日本臨牀　76/増刊1　実施診療のための最新認知症学

出版社： 日本臨牀社
発行日： 2018-01-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 実施診療のための最新認知症学―検査・治療・予防・支援―
電子書籍版： 2018-01-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

16,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

16,500 円(税込)

購入する

目次

  • 特集　実施診療のための最新認知症学―検査・治療・予防・支援―

    序文　認知症を巡る現況と課題

    1．評価法と検査法
    2．薬物治療の進歩
    3．鑑別診断
    4．認知症予防
    5．アルツハイマー病治療薬開発
    6．アルツハイマー病の先進医療とRegistry
    7．新たな視点・問題点
    8．専門職の養成強化
    9．認知症患者とその家族を支える社会支援体制

    アルツハイマー博士と最近の国際学会トピックス

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文 認知症を巡る現況と課題

P.6 掲載の参考文献
1) 荒井啓行 : 先制医療と認知症予防の展望. 日本臨牀 69 (増刊号 8「認知症学 (上)」) : 1-6, 2011.
 
2) 荒井啓行 : アルツハイマー病研究の現状と展望-概論-. 日本臨牀 69 (増刊号 8 「認知症学 (下)」 : 229-235, 2011.
 
3) 荒井啓行, 古川勝敏 : 脳脊髄液タウ蛋白測定の認知症診断への応用と保険収載. 医学のあゆみ 243 : 247-248, 2012.
 
4) 荒井啓行, ほか : アルツハイマー病新薬開発の動向. 日本臨牀 74 : 411-416, 2016.
Medical*Online

I 評価法と検査法

P.15 掲載の参考文献
1) 森悦朗, ほか : 神経疾患患者における日本語版Mini-Mental Stateテストの有用性. 神経心理学 1 : 82-90, 1985.
 
2) 加藤伸司, ほか : 改訂長谷川式簡易認知評価スケール (HDS-R) の作成. 老年精神医学雑誌 2 : 1339-1347, 1991.
 
3) 鈴木宏幸, 藤原佳典 : Montreal Cognitive Assessment (MoCA) の日本語版作成とその有効性について. 老年精神医学雑誌 21 : 198-202, 2010.
Medical*Online
4) Borson S, et al : The Mini-Cog as a screen for dementia : validation in a population-based sample. J Am Geriatr Soc 51 : 1451-1454, 2003.
 
5) Dubois B, et al : The FAB : aFrontal Assessment Battery at bedside. Neurology 55 : 1621-1626, 2000.
 
6) 博野信次, ほか : 日本語版Neuropsychiatric Inventory-痴呆の精神症状評価法の有用性の検討. 脳と神経 49 : 266-271, 1997.
 
P.23 掲載の参考文献
1) Haacke EM, et al : Susceptibility weighted imaging (SWI). Magn Reson Med 52 : 612-618, 2004.
PubMed
2) Murata T, et al : Conspicuity and evolution of lesions in Creutzfeldt-Jakob disease at diffusion-weighted imaging. AJNR Am J Neuroradiol 23 : 1164-1172, 2002.
PubMed
3) 目黒謙一 : 血管性認知症-遂行機能と社会適応能力の障害, p26-32, ワールドプランニング, 2008.
 
4) 松田博史, 朝田隆 : 認知症の画像診断, 改訂第2版, p137-150, 永井書店, 2010.
 
5) Ashburner J, Friston KJ : Voxel-based morphometry-the methods. Neurolmage 11 : 805-821, 2000.
 
6) Hirata Y, et al : Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 382 : 269-274, 2005.
PubMed
7) Gomez-Isla T, et al : Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16 : 4491-4500, 1996.
PubMed
8) 松田博史 : 早期アルツハイマー型認知症診断支援システムVSRADについて. 日本放射線技術学会雑誌 62 : 1066-1072, 2006.
 
9) Frisoni GB, et al : The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 130 : 720-730, 2007.
PubMed
10) Nan K, et al : Phase Information Enables Amyloid Plaque Imaging of the Human Brain on Clinical MRI. Radiological Society of North America 2015.
 
P.31 掲載の参考文献
1) Albert MS, et al : The diagnosis of mild cognitive impairment due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 : 270-279, 2011.
PubMed
2) 奥山智緒 : MCIにおけるMRI/SPECTの役割. 認知症の脳画像診断 (西村恒彦, 武田雅俊編), p77-83, メジカルビュー社, 2015.
 
3) Imabayashi E, et al : The cingulate island sign within early Alzheimer's disease-specific hypoperfusion volumes of interest is useful for differentiating Alzheimer's disease from dementia with Lewy bodies. EJNMMI Res 6 : 67, 2016.
PubMed
4) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 89 : 88-100, 2017.
PubMed
5) Kahraman D, et al : Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease. J Neurol 259 : 251-260, 2012.
PubMed
6) 永山寛 : MIBG心筋シンチグラフィーと神経疾患. 脳循環代謝 22 : 91-96, 2011.
 
7) Yeo JM, et al : Systematic review of the diagnostic utility of SPECT imaging in dementia. Eur Arch Psychiatry Clin Neurosci 263 : 539-552, 2013.
PubMed
8) Ishii K, et al : Computer-assisted system for diagnosing degenerative dementia using cerebral blood flow SPECT and 3D-SSP : a multicenter study. Jpn J Radiol 32 : 383-390, 2014.
PubMed
9) Hanyu H, et al : Comparative value of brain perfusion SPECT and [123I] MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging 33 : 248-253, 2006.
PubMed
10) Shimizu S, et al : Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. Eur J Nucl Med Mol Imaging 43 : 184-192, 2016.
PubMed
11) 伊藤健吾 : EBMツールとしての脳SPECT/PETの役割 2. 認知症 (J-COSMIC, J-ADNIなど). 最新脳SPECT/PETの臨床, 第3版 (西村恒彦編), p181-185, メジカルビュー社, 2012.
 
12) Kasanuki K, et al : 123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 44 : 358-365, 2017.
PubMed
13) Alegret M, et al : Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment. J AIzheimers Dis 41 : 739-748, 2014.
PubMed
P.35 掲載の参考文献
1) Sclan S, Reisberg B : Functional assessment staging (FAST) in Alzheimer's disease : reliability, validity, and ordinality. Int Psychogeriatr 4 (Suppl 1) : 55-69, 1992.
 
2) Mahoney F, Barthel D : Functional Evaluation : The Barthel Index. Md State Med J 14 : 61-65, 1965.
PubMed
3) Keith RA, et al : The functional independence measure : anew tool for rehabilitation. Adv Clin Rehabil 1 : 6-18, 1987.
 
4) Lawton MP, Brody EM : Assessment of older people : self-maintaining and instrumental activities of daily living. Gerontologist 9 : 179-186, 1969.
PubMed
5) Pfeffer RI, et al : Measurement of functional activities in older adults in the community. J Gerontol 37 : 323-329, 1982.
PubMed
6) 古谷野亘, ほか : 地域老人における活動能力の測定-老研式活動能力指標の開発. 日本公衆衛生雑誌 34 : 109-114, 1987.
 
7) Iwasa H, et al : Development of the Japan Science and Technology Agency Index of Competence to Assess Functional Capacity in Older Adults : Conceptual Definitions and Preliminary Items. Gerontol Geriatr Med 1, 2015. (doi : 10. 1177/2333721415609490)
 
8) Morris JC : The Clinical Dementia Rating (CDR) : current version and scoring rules. Neurology 43 : 2412-2414, 1993.
PubMed
9) 粟田主一, ほか : 地域在住高齢者を対象とする地域包括ケアシステムにおける認知症アセスメントシート (DASC-21) の内的信頼性・妥当性に関する研究. 老年精神医学雑誌26 : 675-686, 2015.
 
10) 粟田主一 : 認知症初期集中支援チーム実践テキストブック-DASCによる認知症アセスメントと初期支援, 中央法規出版, 2015.
 
P.42 掲載の参考文献
1) Rubenstein LZ, Rubenstein LV : Multidimensional geriatric assessment. In : Brocklehurst's Textbook of Geriatric Medicine and Gerontology, 8th edition (ed by Fillit HM, et al), p213-221, Elsevier, Philadelphia, 2016.
 
2) Ward KT, et al : Comprehensive geriatric assessment. UpToDate 2017.
 
3) Ritch A : History of geriatric medicine : from Hippocrates to Marjory Warren. J R Coll Physicians Edinb 42 : 368-374, 2012.
 
4) 小澤利男 : 老年医学の道を歩んで-総合機能評価CGAの導入と発展を考える. 日本老年医学会雑誌 54 : 211-221, 2017.
 
5) 長寿科学総合研究CGAガイドライン研究班 : 高齢者総合的機能評価ガイドライン, 厚生科学研究所, 2003.
 
6) Rubenstein LZ, et al : Effectiveness of a geriatric evaluation unit. A randomized clinical trial. N Engl J Med 311 : 1664-1670, 1984.
PubMed
7) Stuck AE, et al : Comprehensive geriatric assessment : ameta-analysis of controlled trials. Lancet 342 : 1032-1036, 1993.
 
8) Ellis G, et al : Comprehensive geriatric assessment for older adults admitted to hospital : meta-analysis of randomized controlled trials. BMJ 343, 2011. (doi : 10. 1136/bmj. d6553.) (Cochrane Database Syst Rev (7) : CDOO6211, 2011.)
 
9) World Health Organization. Health of the elderly. WHO, Geneva, 1989.
 
10) 世界保健機構 (WHO) : 国際生活機能分類-国際障害分類改定版 (障害者福祉研究会編), 中央法規出版, 2002.
 
11) 上田敏 : ICF (国際生活機能分類) の理解と活用-人が「生きること」「生きることの困難 (障害)」をどうとらえるか, きょうされん, 萌文社, 2005.
 
12) Bickenbach JE, ほか : ICFコアセット 臨床実践のためのマニュアル (公益社団法人日本リハビリテーション医学会監訳), 医歯薬出版, 2015.
 
13) 冨田尚希 : 高齢者薬物療法の系統的なスクリーニング・アセスメント・サポート法の構築. 公益財団法人長寿科学振興財団長寿科学の最前線 Vol. 2, 長寿科学研究者支援事業平成26年度研究報告集.
 
14) Tomita N, Tsuchiya T : Effects of Grouping Alternatives on Eliciting More Responses to Check-All-That-Apply Questions. International Conference on Questionnaire Design, Development, Evaluation, and Testing (QDET2), Nov. 10, 2016 Miami, FL.
 
15) Wildiers H, et al : International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32 : 2595-2603, 2014.
 
P.49 掲載の参考文献
1) Sonnen JA, et al : Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 62 : 406-413, 2007.
 
2) White L, et al : Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci 977 : 9-23, 2002.
 
3) Sonnen JA, et al : Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. J Alzheimers Dis 19 : 301-309, 2010.
 
4) 日本神経学会 (監修), 「認知症疾患診療ガイドライン」作成委員会 (編) : 認知症疾患, 診療ガイドライン 2017, p42-43, 医学書院, 2017.
 
5) Gonzalez-Cuyar LF, et al : Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment. Curr Neurol Neurosci Rep 11 : 455-463, 2011.
PubMed
6) Sunderland T, et al : Decreased beta-amyloidl-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 : 2094-2103, 2003.
 
7) Welge V, et al : Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) 116 : 203-212, 2009.
 
8) Li G, et al : CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment : a follow-up study. Neurology 69 : 631-639, 2007.
PubMed
9) Zetterberg H, et al : Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65 : 1102-1107, 2008.
PubMed
10) van Harten AC, et al : Tau and p-tau as CSF-biomarkers in dementia : a meta-analysis. Clin Chem Lab Med 49 : 353-366, 2011.
PubMed
11) Vanderstichele H, et al : Analytical performance and clinical utility of the INNOTEST PHOSPHOTAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 44 : 1472-1480, 2006.
PubMed
12) Bibl M, et al : CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129 : 1177-1187, 2006.
PubMed
13) Alves G, et al : CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease : the Norwegian Park West study. J Neurol Neurosurg Psychiatr 81 : 1080-1086, 2010.
 
14) Siderowf A, et al : CSF amyloid ｛beta｝1-42 predicts cognitive decline in Parkinson disease. Neurology 75 : 1055-1061, 2010.
PubMed
15) Montine TJ, et al : CSF Aβ (42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 25 : 2682-2685, 2010.
 
16) Mollenhauer B, et al : α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism : a cohort study. Lancet Neurol 10 : 230-240, 2011.
 
17) Shi M, et al : Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69 : 570-580, 2011.
PubMed
18) Tokuda T, et al : Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75 : 1766-1772, 2010.
 
19) Waragai M, et al : Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 345 : 967-972, 2006.
PubMed
20) Hong Z, et al : DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133 : 713-726, 2010.
PubMed
21) Maruyama M, et al : Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment : implications for 2 major pathways. Arch Neurol 61 : 716-720, 2004.
PubMed
22) Sjogren M, et al : Neurofilament protein in cerebrospinal fluid : a marker of white matter changes. J Neurosci Res 66 : 510-516, 2001.
PubMed
23) Bian H, et al : CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70 : 1827-1835, 2008.
PubMed
P.54 掲載の参考文献
1) Jack CR Jr, et al : Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 : 257-262, 2011.
 
2) Omachi Y, et al : Clinical impact of (11) C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment. Psychiatry Clin Neurosci 69 : 741-751, 2015.
PubMed
3) Ossenkoppele R, et al : Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 9 : 414-421, 2013.
 
4) Adlard PA, et al : A review of β-amyloid neuroimaging in Alzheimer's disease. Front Neurosci 8 : 327, 2014.
 
5) Zhang S, et al : (11) C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev (7) : CD010386, 2014.
PubMed
6) Catafau AM, Bullich S : Amyloid PET imaging : applications beyond Alzheimer's disease. Clin Transl Imaging 3 : 39-55, 2015.
PubMed
7) Dubroff JG, Nasrallah IM : Will PET amyloid imaging lead to overdiagnosis of Alzheimer dementia? Acad Radiol 22 : 988-994, 2015.
PubMed
8) Johnson KA, et al : Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79 : 110-119, 2016.
PubMed
9) Sone D, et al : Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease : A combined PET/MRI study. Alzheimers Dement (Amst) 9 : 35-40, 2017.
PubMed
10) Ng KP, et al : Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther 9 : 25, 2017.
PubMed
11) Jack CR, et al : Suspected non-Alzheimer disease pathophysiology-concept and controversy. Nat Rev Neurol 12 : 117-124, 2016.
PubMed
12) Jack CR, et al : An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71 : 765-775, 2012.
PubMed
13) Petersen RC, et al : Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74 : 199-208, 2013.
PubMed
14) Caroli A, et al : Mild cognitive impairment with suspected nonamyloid pathology (SNAP) : Prediction of progression. Neurology 84 : 508-515, 2015.
PubMed
15) Crary JF, et al : Primary age-related tauopathy (PART) : acommon pathology associated with human aging. Acta Neuropathol 128 : 755-766, 2014.
 

II. 薬物治療の進歩

P.60 掲載の参考文献
1) 鳥羽研二, ほか : 薬剤起因性疾患. 日本老年医学会雑誌 36 : 181-185, 1999.
 
2) Kojima T, et al : High risk of adverse drug reactions in elderly patients taking six or more drugs : analysis of inpatient database. Geriatr Gerontol Int 12 : 761-762, 2012.
PubMed
3) Kojima T, et al : Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int 12 : 425-430, 2012.
PubMed
4) Rothschild JM, et al : Preventable medical injuries in older patients. Arch lntern Med 160 : 2717-2728, 2000.
PubMed
5) 秋下雅弘 (編) : 高齢者のための薬の使い方, ぱーそん書房, 2013.
 
6) 秋下雅弘, ほか : 高齢者の服薬状況および副作用に関する検討. 日本老年医学会雑誌 32 : 178-182, 1995.
 
7) The American Geriatrics Society 2015 Beers Criteria Update Expert Panel : American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 63 : 2227-2246, 2015.
 
8) O'Mahony D, et al : STOPP/START criteria for potentially inappropriate prescribing in older people : version 2. Age Ageing 44 : 213-218, 2015.
PubMed
9) 日本老年医学会, 日本医療研究開発機構研究費・高齢者の薬物治療の安全性に関する研究研究班 (編) : 高齢者の安全な薬物療法ガイドライン 2015. メジカルビュー社, 2015.
 
P.67 掲載の参考文献
1) Bowen DM, et al : Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99 : 459-496, 1976.
PubMed
2) Davies P, Maloney AJ : Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 : 1403, 1976.
PubMed
3) Whitehouse PJ, et al : Alzheimer's disease and senile dementia : loss of neurons in the basal forebrain. Science 215 : 1237-1239, 1982.
PubMed
4) Geula C, Mesulam MM : Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex 6 : 165-177, 1996.
PubMed
5) Takada Y, et al : Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 306 : 772-777, 2003.
PubMed
6) Meunier J, et al : The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigmal receptor. Br J pharmacol 149 : 998-1012, 2006.
 
7) Kotani S, et al : Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. Neuroscience 142 : 505-514, 2006.
PubMed
8) Hashimoto M, et al : Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 162 : 676-682, 2005.
PubMed
9) Krishnan KR, et al : Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160 : 2003-2011, 2003.
PubMed
10) Dubois B, et al : Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimers Dement 11 : 1041-1049, 2015.
PubMed
11) Rogers SL, et al : Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease : final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 10 : 195-203, 2000.
PubMed
12) Mohs RC, et al : A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 : 481-488, 2001.
PubMed
13) Winblad B, et al : Donepezil treatment in severe Alzheimer's disease : apooled analysis of three clinical trials. Curr Med Res Opin 25 : 2577-2587, 2009.
PubMed
14) Inoue J, et al : Investigation of responders and non-responders to long-term donepezil treatment. Psychogeriatrics 10 : 53-61, 2010.
 
15) McKeith I, et al : Efficacy of rivastigmine in dementia with Lewy bodies : arandomised, double-blind, placebo-controlled international study. Lancet 356 : 2031-2036, 2000.
 
16) Holmes C, et al : The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63 : 214-219, 2004.
PubMed
17) Gauthier S, et al : Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 14 : 389-404, 2002.
PubMed
18) Birks J, Flicker L : Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 19 : CD006104, 2006.
 
19) Manabe Y, et al : Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies. Psychogeriatrics 16 : 202-208, 2016.
PubMed
P.73 掲載の参考文献
1) Bowen DM, et al : Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99 : 459-496, 1976.
PubMed
2) Davies P, Maloney AJ : Selective loss of central cholinergic neurons in Alzheimergs disease. Lancet 2 : 1403, 1976.
PubMed
3) Geula C, Mesulam M : Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex 6 : 165-177, 19. 9 6.
 
4) Whitehouse PJ, et al : Alzheimer disease : evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10 : 122-126, 1981.
PubMed
5) Shimohama S, et al : Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia J Neurochem 46 : 288-293, 1986.
PubMed
6) Kadir A, et al : PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 29 : 1204-1217, 2008.
PubMed
7) Maelicke A : Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 11 (Suppl 1) : 11-18, 2000.
 
8) Weigand SD, et al : Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβamyloid. Alzheimers Dement 7 : 133-141, 2011.
 
9) Nordberg A, et al : Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 6 : 4-14, 2009.
PubMed
10) Takata K, et al : Galantamine-induced amyloid- ｛beta｝ clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285 : 40180-40191, 2010.
PubMed
11) Henneman WJ, et al : Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 73 : 935-940, 2009.
PubMed
12) Arias E, et al : Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells : role of nicotinic receptors. J Pharmacol Exp Ther 315 : 1346-1353, 2005.
 
13) Takada-Takatori Y, et al : Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51 : 474-486, 2006.
PubMed
14) Kihara T, et al : alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 276 : 13541-13546, 2001.
 
15) Wahlund LO, Blennow K : Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339 : 99-102, 2003.
PubMed
16) DeKosky ST, et al : Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51 : 145-155, 2002.
PubMed
17) Garcia-Alloza M, et al : Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43 : 442-449, 2005.
PubMed
18) Matthews KL, et al : Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 51 : 407-416, 2002.
PubMed
19) Mitchell RA, et al : The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neurosci Ther 17 : 411-427, 2011.
PubMed
20) Davis B, Sadik K : Circadian cholinergic rhythms : implications for cholinesterase inhibitor therapy. Dement Geriatr Cogn Disord 21 : 120-129, 2006.
PubMed
21) Ishida T, et al : Effects of anti-dementia drugs on sleep-wake patterns in sleep-disturbed rats. Nihon Shinkei Seishin Yakurigaku Zasshi 29 : 17-22, 2009.
PubMed
22) Loy C, Schneider L : Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev (1) : CD001747, 2006.
PubMed
23) Burns A, et al : Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study) : a randomised, placebo-controlled, double-blind trial. Lancet Neurol 8 : 39-47, 2009.
PubMed
24) 本間昭, ほか : ガランタミン臭化水素酸塩のアルツハイマー型認知症に対するプラセポ対照二重盲検比較試験, 老年精神医学雑誌 22 : 333-345, 2011.
 
25) Hansen RA, et al : Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease : a systematic review and meta-analysis. Clin Interv Aging 3 : 211-225, 2008.
PubMed
26) Birks J : Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (1) : CD005593, 2006.
 
27) 繁田雅弘, ほか : ドネペジル, ガランタミン, リバスチグミンのアルツハイマー型認知症に対する有効性の比較検討 : 国内第3相試験を統合した有効性の間接比較Geriatric Medicine 51 : 957-963, 2013.
 
28) 下濱俊 : ガランタミンの基礎と特徴. MEDICINAL 2 : 25-34, 2012.
 
P.81 掲載の参考文献
1) Cerbai F, et al : Nlphenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex : a comparison with donepezil and rivastigmine. Eur J Pharmacol 572 : 142-150, 2007.
PubMed
2) Darvesh S, et al : Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 393 : 374-390, 1998.
PubMed
3) Darvesh S, Hopkins DA : Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 463 : 25-43, 2003.
 
4) 野田泰葉, ほか : 軽度アルツハイマー型認知症患者の記憶障害に対するリバスチグミンの効果. 新薬と臨床 64 : 152-158, 2015.
Medical*Online
5) 眞鍋雄太, 小阪憲司 : アルツハイマー型認知症の活動性の改善におけるリバスチグミン貼付剤の有用性に関する検討. 臨床精神医学 45 : 853-857, 2016.
Medical*Online
6) 中村祐, ほか : 軽度および中等度アルツハイマー型認知症患者を対象としたrivastigmineパッチの国内第IIb/III相試験における事後の追加解析結果. 臨床神経薬理 15 : 575-583, 2012.
 
7) Cummings JL, et al : Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease : a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 3 : 137-148, 2005.
PubMed
8) De Vriese C, et al : Ghrelin degradation by serum and tissue homogenates : identification of the cleavage sites. Endocrinology 145 : 4997-5005, 2004.
PubMed
9) Winblad B, et al : Caregiver preference for rivastigmine patch relative to capsule for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 22 : 485-491, 2007.
PubMed
10) Nakamura Y, et al : A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra 1 : 163-179, 2011.
 
11) 加藤豊範 : リバスチグミン服薬継続率向上の取り組み. Progress in Medicine 36 : 1561-1569, 2016.
 
12) Nakamura Y, et al : A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease. Dement Geriatr Cogn Dis Extra 5 : 361-374, 2015.
 
13) Cagnin A, et al : Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors : a naturalistic prospective study in Alzheimer's disease. Neurol Sci 36 : 457-463, 2015.
 
14) 中村祐, ほか : 軽度および中等度アルツハイマー型認知症患者へのリバスチグミンパッチ投与による血漿中ブチリルコリンエステラーゼ活性の変化と認知機能に対する作用の関係-国内第IIb/III相試験における事後解析-. 老年精神医学雑誌 25 : 566-574, 2014.
Medical*Online
15) 野田泰葉, ほか : ITを用いた認知症患者の服薬管理支援システム. 癌と化学療法 41 (Suppl I) : 30-32, 2014.
 
P.86 掲載の参考文献
1) Danysz W, et al : Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev 21 : 455-468, 1997.
PubMed
2) Parsons CG, et al : Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3, 5-dimethyladamantan). Neuropharmacology 32 : 1337-1350, 1993.
 
3) Frankiewicz T, Parsons CG : Memantine restores long term potentiation impaired by tonic NMDA receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology 38 : 1253-1259, 1999.
PubMed
4) Wenk GL, et al : MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J pharmacol 293 : 267-270, 1995.
PubMed
5) Reisberg B, et al : Senile dementia of the Alzheimer type : Diagnostic and differential diagnostic features with special reference to functional assessment staging. In : Senile Dementia of the Alzheimer Type : Early Diagnosis, Neuropathology and Animal Models (ed by Traber J, Gispen WH), p18-37, Springer-Verlag, Berlin, 1985.
 
6) 中村祐, ほか : 新規NMDA受容体拮抗剤であるメマンチン塩酸塩の中等度から高度アルツハイマー型認知症に対する第III相試験-有効性および安全性の検討-. 老年精神医学雑誌 22 : 464-473, 2011.
Medical*Online
7) 中村祐 : 介護サービスの利用による認知症患者の介護状況の変化に関する調査とその変化がCIBIC-plus評価に及ぼす影響についての考察. 老年精神医学雑誌 21 : 685-694, 2010.
Medical*Online
8) 北村伸, ほか : 新規NMDA受容体拮抗剤であるメマンチン塩酸塩の中等度から高度アルツハイマー型認知症に対する後期第II相試験-有効性・安全性および推奨用量の検討-. 老年精神医学雑誌 22 : 453-463, 2011.
Medical*Online
9) Gauthier S, et al : Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine : apooled data analysis. Int J Geriatr Psychiatry 23 : 537-545, 2008.
PubMed
10) 本間昭, ほか : メマンチン塩酸塩のアルツハイマー型認知症患者に関する安全性および有効性-メマンチン塩酸塩長期使用に関する特定使用成績調査の中間集計結果-. 老年精神医学雑誌 25 : 419-433, 2014.
Medical*Online
11) 本間昭, ほか : メマンチン塩酸塩のアルツハイマー型認知症患者における長期使用の安全性および有効性-メマリー錠・OD錠長期使用に関する特定使用成績調査の36か月データ解析結果-. 老年精神医学雑誌 28 : 651-662, 2017.
Medical*Online
12) 北村伸, ほか : メマンチン塩酸塩 (メマリー) の中等度および高度アルツハイマー型認知症に対する長期投与時の忍容性ならびに有効性の検討. 日本老年医学会雑誌 51 : 74-84, 2014.
 
13) 北村伸, ほか : 中等度および高度アルツハイマー型認知症患者に対するメマンチン単剤療法の費用効果分析. 老年精神医学雑誌 25 : 1361-1373, 2014.
Medical*Online
P.94 掲載の参考文献
1) 日本神経学会 (監), 「認知症疾患診療ガイドライン」作成委員会 (編) : 認知症疾患診療ガイドライン 2017, 医学書院, 2017.
 
2) Nakamura Y, Yoshiyama Y : Cognitive Function and Calcium. Suppression of neurotoxicity by an anti-dementia drug managing calcium influx. Clin Calcium 25 : 263-273, 2015.
PubMed
3) Tariot PN, et al : Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil : a randomized controlled trial. JAMA 291 : 317-324, 2004.
PubMed
4) Howard R, et al : Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366 : 893-903, 2012.
PubMed
5) 中村祐, ほか : メマンチン塩酸塩のドネペジル塩酸塩併用時における中等度および高度アルツハイマー型認知症に対する有効性および安全性. Geriatric Medicine 54 : 1147-1158, 2016.
Medical*Online
6) 中村祐, ほか : アルツハイマー型認知症に対するドネペジル塩酸塩, メマンチン製剤併用時の安全性および有効性 (アリセプト特定使用成績調査). Geriatric Medicine 55 : 87-100, 2017.
 
7) Matsunaga S, et al : Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease : a systematic review and meta-analysis. Int J Neuropsychopharmacol 18, 2015. (doi : 10. 1093/ijnp/pyu115)
 
P.98 掲載の参考文献
1) Iwasaki K, et al : A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine "ba wei di huang wan" in the treatment of dementia. J Am Geriatr Soc 52 : 1518-1521, 2004.
PubMed
2) Maruyama M, et al : Benefits of combining donepezil plus traditional Japanese herbal medicine on cognition and brain perfusion in Alzheimer's disease : a 12-week observer-blind, donepezil monotherapy controlled trial. J Am Geriatr Soc 54 : 869-871, 2006.
 
3) Kudoh C, et al : Effect of ninjin' yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease : 2 years of observation. Psychogeriatrics 16 : 85-92, 2016.
PubMed
4) Yabe T, et al : Enhancements of choline acetyltransferase activity and nerve growth factor secretion by Polygalae radix-extract containing active ingredients in Kami-untan-to. Phytomedicine 4 : 199-205, 1997.
PubMed
5) Iwasaki K, et al : Arandomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 66 : 248-252, 2005.
 
6) Mizukami K, et al : Arandomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol 12 : 191-199, 2009.
 
7) Monji A, et al : Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 33 : 308-311, 2009.
PubMed
8) Okahara K, et al : Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 34 : 532-536, 2010.
PubMed
9) Furukawa K, et al : Randomized double-blind placebo- controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease. Geriatr Gerontol Int 17 : 211-218, 2017.
PubMed
10) Matsunaga S, et al : Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia : An Updated Meta-Analysis of Randomized Controlled Trials. J AIzheimers Dis 54 : 635-643, 2016.
PubMed
11) Terawaki K, et al : Partial agonistic effect of yokukansan on human recombinant serotonin IA receptors expressed in the membranes of Chinese hamster ovary cells. J Ethnopharmacol 127 : 306-312, 2010.
 
12) Nishi A, et al : Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin 1A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansan. Neuroscience 207 : 124-136, 2012.
PubMed
13) Egashira N, et al : Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT) 2A receptors in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 32 : 1516-1520, 2008.
PubMed
14) Takeda A, et al : Attenuation of abnormal glutamate release in zinc deficiency by zinc and Yokukansan. Neurochem Int 53 : 230-235, 2008.
PubMed
15) Kawakami Z, et al : Glycyrrhizin and its metabolite 18 beta-glycyrrhetinic acid in glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes. Eur J pharmacol 626 : 154-158, 2010.
PubMed
16) Takeda A, et al : Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats. Nutr Neurosci 11 : 41-46, 2008.
PubMed
17) 馬込敦 : 認知症に対する抑肝散加陳皮半夏の効果-東洋医学的観点も加えて-. 精神科 18 : 108-114, 2011.
 
18) 宮澤仁朗 : 精神科薬理 アルツハイマー型認知症に対する抑肝散加陳皮半夏の臨床的検討. 精神科 14 : 535-542, 2009.
 
19) Shimada Y, et al : Chotosan and cerebrovascular disorders : Clinical and experimental studies. J Trad 23, 117-131, 2006.
 
20) Terasawa K, et al : Choto-san in the treatment of vascular dementia : a double-blind, placebo-controlled study. Phytomedicine 4 : 15-22, 1997.
PubMed
21) 日本老年医学会, 日本医療研究開発機構研究費・高齢者の薬物治療の安全性に関する研究研究班 (編) : 高齢者の安全な薬物療法ガイドライン 2015, メジカルビュー社, 2015.
 
P.104 掲載の参考文献
1) 平成27年度厚生労働科学研究費補助金 (厚生労働科学特別研究事業) 認知症に対するかかりつけ 医の向精神薬使用の適正化に関する調査研究班 : 認知症に対するかかりつけ医の向精神薬使用の適正化に関する調査研究, 2015.
 
2) U. S. Food and Drug Administration (FDA) : Public Health Advisory : Deaths with antipsychotics in elderly patients with behavioral disturbances. (Accessed November 3, 2005) [https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucmO53171] (2017年10月閲覧)
 
3) Arai H, et al : Mortality risk in current and new antipsychotic Alzheimer's disease users : Large scale Japanese study. Alzheimers Dement 12 : 823-830, 2016.
PubMed
4) かかりつけ医のためのBPSDに対応する向精神薬使用ガイドライン (第2版) [http://www.mhlw.gojp/stf/seisakunitsuite/bunya/0000135953.html] (2017年8月閲覧)
 

III 鑑別診断

P.121 掲載の参考文献
1) Albert MS, et al : The diagnosis of mild cognitive impairment due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 : 270-279, 2011.
PubMed
2) McKhann GM, et al : The diagnosis of dementia due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 : 263-269, 2011.
 
3) Sperling RA, et al : Toward defining the preclinical stages of Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 : 280-292, 2011.
PubMed
4) Alberdi A, et al : On the early diagnosis of Alzheimer's Disease from multimodal signals : A survey. Artif Intell Med 71 : 1-29, 2016.
PubMed
5) 小松美和, ほか : アルツハイマー病の分類・病期と診断. 老年精神医学雑誌 22 : 1073-1078, 2011.
Medical*Online
6) Kazui H, et al : Differences of Behavioral and Psychological Symptoms of Dementia in Disease Severity in Four Major Dementias. PLoS ONE 11 : e0161092, 2016.
PubMed
7) Murayama N, et al : Risk factors for delusion of theft in patients with Alzheimer's disease showing mild dementia in Japan. Aging Ment Health 13 : 563-568, 2009.
PubMed
8) Dubois B, et al : Advancing research diagnostic criteria for Alzheimer's disease : the IWG-2 criteria. Lancet Neurol 13 : 614-629, 2014.
PubMed
9) Gorno-Tempini ML, et al : Classification of primary progressive aphasia and its variants. Neurology 76 : 1006-1014, 2011.
PubMed
10) Matsuda H : MRI morphometry in Alzheimer's disease. Ageing Res Rev 30 : 17-24, 2016.
PubMed
11) Matsuda H, et al : An easy Z-score imaging system for discrimination between very early Alzheimer's disease and controls using brain perfusion SPECT in a multicentre study. Nucl Med Commun 28 : 199-205, 2007.
 
12) Zhao Q, et al : Quantitative multimodal multiparametric imaging in Alzheimer's disease. Brain Inform 3 : 29-37, 2016.
PubMed
13) Fu L, et al : Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis. Eur Radiol 24 : 2800-2809, 2014.
PubMed
14) Morris E, et al : Diagnostic accuracy of (18) F amyloid PET tracers for the diagnosis of Alzheimer's disease : a systematic review and meta-analysis. Eur J Nucl Med Mol lmaging'43 : 374-385, 2016.
 
15) Kang JH, et al : Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β (1-42) andτproteins as Alzheimer disease biomarkers. Clin Chem 59 : 903-916, 2013.
 
16) Yuan Y, et al : Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment : ameta-analysis. AJNR Am J Neuroradiol 30 : 404-410, 2009.
 
17) Hansson O, et al : Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment : afollow-up study. Lancet Neurol 5 : 228-234, 2006.
 
18) 日本精神神経学会 (日本語版用語監修), 高橋三郎・大野裕 (監訳) : 認知症 (DSM-5) および軽度認知障害 (DSM-5), アルツハイマー病による認知症 (DSM-5) およびアルツハイマー病による軽度認知障害 (DSM-5). DSM-5 精神疾患の診断・統計マニュアル, p594-597, p602-603, 医学書院, 2014.
 
19) Llorens F, et al : CSF biomarkers in neurodegenerative and vascular dementias. Prog Neurobiol 138-140 : 36-53, 2016.
 
20) Shyu WC, et al : Vascular dementia of Binswanger's type : clinical, neuroradiological and 99mTc-HMPAO SPET study. Eur J Nucl Med 23 : 1338-1344, 1996.
PubMed
21) Kerrouche N, et al : 18FDG PET in vascular dementia : differentiation from Alzheimer's disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab 26 : 1213-1221, 2006.
PubMed
22) McKeith IG, et al : Diagnosis and managernent of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 89 : 88-100, 2017.
PubMed
23) Bott NT, et al : Frontotemporal dementia : diagnosis, deficits and management. Neurodegener Dis Manag 4 : 439-454, 2014.
PubMed
24) Yamada M : Senile dementia of the neurofibrillary tangle type (tangle-only dementia) : neuropathological criteria and clinical guidelines for diagnosis. Neuropathology 23 : 311-317, 2003.
PubMed
25) Tolnay M, Clavaguera F : Argyrophilic grain disease : alate-onset dementia with distinctive features among tauopathies. Neuropathology 24 : 269-283, 2004.
 
26) Adachi T, et al : Neuropathological asymmetry in argyrophilic grain disease. J Neuropathol Exp Neurol 69 : 737-744, 2010.
 
27) Gallia GL, et al : The diagnosis and treatment of idiopathic normal pressure hydrocephalus. Nat Clin Pract Neurol 2 : 375-381, 2006.
PubMed
28) Parchi P, et al : Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46 : 224-233, 1999.
 
29) Nozaki I, et al : Prospective 10-year surveillance of human prion diseases in Japan. Brain 133 : 3043-3057, 2010.
PubMed
30) Shiga Y, et al : Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology 63 : 443-449, 2004.
PubMed
31) Hamaguchi T, et al : Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology 64 : 643-648, 2005.
PubMed
32) Noguchi-Shinohara M, et al : Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease. J Neurol 258 : 1464-1468, 2011.
PubMed
33) Satoh K, et al : Real-Time Quaking-lnduced Conversion for Diagnosis of Prion Disease. Methods Mol Biol 1658 : 305-310, 2017.
 
P.129 掲載の参考文献
1) Gomperts SN : Lewy Body Dementias : Dementia With Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneap Minn) 22 : 435-463, 2016.
PubMed
2) Kosaka K, et al : Presenile dementia with Alzheimer-, Pick-and Lewy-body changes. Acta Neuropathol 36 : 221-233, 1976.
PubMed
3) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 65 : 1863-1872, 2005.
PubMed
4) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 89 : 88-100, 2017.
PubMed
5) David AS, et al : Lishman's Organic Psychiatry : A Textbook of Neuropsychiatry, 4th ed, Wiley-Blackwell, Chichester, 2012.
 
6) Obeso JA, et al : The expanding universe of disorders of the basal ganglia. Lancet 384 : 523-531, 2014.
PubMed
7) Ala TA, et al : The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 17 : 503-509, 2002.
PubMed
8) Lee DR, et al : The dementia cognitive fluctuation scale, a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia. Am J Geriatr Psychiatry 22 : 926-935, 2014.
PubMed
9) Ffytche DH, et al : The psychosis spectrum in Parkinson disease. Nat Rev Neurol 13 : 81-95, 2017.
PubMed
10) Postuma RB, et al : MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30 : 1591-1601, 2015.
PubMed
11) Miyamoto T, et al : The REM sleep behavior disorder screening questionnaire : validation study of a Japanese version. Sleep Med 10 : 1151-1154, 2009.
PubMed
12) Orimo S, et al : Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131 : 642-650, 2008.
PubMed
13) Mori E, et al ; Donepezil-DLB Study Investigators : Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled trial. Ann Neurol. 72 : 41-52, 2012.
 
P.136 掲載の参考文献
1) Tomlinson BE, et al : Observations on the brains of demented old people. J Neurol Sci 11 : 205-242, 1970.
 
2) Bowler JV, Hachinski V : Vascular cognitive impairment : a new approach to vascular dementia. Baillieres Clin Neurol 4 : 357-376, 1995.
PubMed
3) Jellinger KA, Attems J : Is there pure vascular dementia in old age? J Neurol Sci 299 : 150-154, 2010.
 
4) Thal DR, et al : Vascular pathology in Alzheimer disease : correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 62 : 1287-1301, 2003.
PubMed
5) Kumar S, et al : Atraumatic convexal subarachnoid hemorrhage : clinical presentation, imaging patterns, and etiologies. Neurology 74 : 893-899, 2010.
PubMed
6) Jouvent E, et al : Intracortical infarcts in small vessel disease : acombined 7-T postmortem MRI and neuropathological case study in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke 42 : e27-30, 2011.
 
7) Lee JH, et al : Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology 77 : 18-25, 2011.
PubMed
8) Yoshitake T, et al : Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population : the Hisayama Study. Neurology 45 : 1161-1168, 1995.
 
9) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342 : 1255-1262, 1993.
 
10) Cao L, et al : Cognitive Function : Is There More to Anticoagulation in Atrial Fibrillation Than Stroke? J Am Heart Assoc 4 : e001573, 2015.
PubMed
11) Petrovitch H, et al : AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol 57 : 98-103, 2005.
PubMed
12) Kyrtsos CR, Baras JS : Modeling the Role of the Glymphatic Pathway and Cerebral Blood Vessel Properties in Alzheimer's Disease Pathogenesis : PLoS One 10 : e0139574, 2015.
PubMed
13) Carare RO, et al : Review : cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol 39 : 593-611, 2013.
 
14) Yamada M, et al : The influence of chronic cerebral hypoperfusion on cognitive function and amyloid β metabolism in APP overexpressing mice. PLoS One 6 : e16567, 2011.
 
15) Farrall AJ, Wardlaw JM : Blood-brain barrier : ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 30 : 337-352, 2009.
PubMed
P.141 掲載の参考文献
1) Neary D, et al : Frontotemporal lobar degeneration : aconsensus on clinical diagnostic criteria. Neurology 51 : 1546-1554, 1998.
 
2) Karageorgiou E, et al : Frontotemporal lobar degeneration : a clinical approach. Semin Neurol 34 : 189-201, 2014.
PubMed
3) 川勝忍, ほか : 運動ニューロン疾患を伴う前頭側頭型認知症 (湯浅・三山病) の病態と診断. 精神医学 57 : 849-856, 2015.
 
4) Rohrer JD, et al : TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 75 : 2204-2211, 2010.
PubMed
5) 池田学, ほか : 進行性失語の概念と診断. 高次脳機能研究 33 : 304-309, 2013.
 
6) Rascovsky K, et al : Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134 : 2456-2477, 2011.
PubMed
7) Harris JM, et al : Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia. Neurology 80 : 1881-1887, 2013.
PubMed
8) Vijverberg EG, et al : Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. Dement Geriatr Cogn Disord 41 : 210-219, 2016.
PubMed
9) The Lund and Manchester Groups : Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 57 : 416-418, 1994.
PubMed
10) Whitwell JL et al : Voxel-based morphometry in tau-positive and tau-negative frontotemporal lobar degenerations. Neurodegener Dis 1 : 225-230, 2004.
PubMed
11) Whitwell JL, et al : Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration. Neurology 66 : 102-104, 2006.
PubMed
12) Rankin KP, et al : Behavioral variant frontotemporal dementia with corticobasal degeneration pathology : phenotypic comparison to bvFTD with Pick's disease. J Mol Neurosci 45 : 594-608, 2011.
PubMed
13) Gorno-Tempini ML, et al : Classification of primary progressive aphasia and its variants. Neurology 76 : 1006-1014, 2011.
PubMed
14) 橋本衛ほか : Semantic dementiaの言語障害の本質とは何か. 高次脳機能研究 35 : 304-311, 2015.
 
15) 大槻美佳 : 進行性非流暢性失語症. 神経心理学 26 : 272-282, 2010.
 
P.147 掲載の参考文献
1) Hiraoka K, et al : Prevalence of idiopathic normal-pressure hydrocephalus in the elderly population of a Japanese rural community. Neurol Med Chir (Tokyo) 48 : 197-199 ; discussion 199-200, 2008.
 
2) Iseki C, et al : Asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus on MRI (AVIM) in the elderly : a prospective study in a Japanese population. J Neurol Sci 277 : 54-57, 2009.
 
3) Tanaka N, et al : Prevalence of possible idiopathic normal-pressure hydrocephalus in Japan : the Osaki-Tajiri project, Neuroepidemiology 32 : 171-175, 2009.
PubMed
4) Kuriyama N, et al : Nationwide hospital-based survey of idiopathic normal pressure hydrocephalus in Japan : Epidemiological and clinical characteristics. Brain Behav 7 : e00635, 2017.
PubMed
5) Israelsson H, et al : Vascular risk factors in INPH : A prospective case-control study (the INPH-CRasH study). Neurology 88 : 577-585, 2017.
PubMed
6) 栗山長門, ほか : 特発性正常圧水頭症の疫学, 病理 (特集 特発性正常圧水頭症 : Update). 老年精神医学雑誌 23 : 800-806, 2012.
 
7) 日本正常圧水頭症学会特発性正常圧水頭症診療ガイドライン作成委員会 (編) : 特発性正常圧水頭症診療ガイドライン, 第2版, メディカルレビュー社, 2011.
 
8) 森悦朗 : 特発性正常圧水頭症の歩行障害. Brain Nerve 60 : 219-224, 2008.
 
9) Hashimoto M, et al : Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme : aprospective cohort study. Cerebrospinal Fluid Res 7 : 18, 2010.
 
10) Morishita T, et al : INPH and Parkinson disease : differentiation by levodopa response. Nat Rev Neurol 6 : 52-56, 2010.
PubMed
11) Andren K, et al : Natural course of idiopathic normal pressure hydrocephalus. J Neurol Neurosurg Psychiatr 85 : 806-810, 2014.
 
12) Kazui H, et al : Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (SINPHONI-2) : an open-label randomised trial. Lancet Neurol 14 : 585-594, 2015.
PubMed
13) Miyajima M, et al : One-year outcome in patients with idiopathic normal-pressure hydrocephalus : comparison of lumboperitoneal shunt to ventriculoperitoneal shunt. J Neurosurg 125 : 1483-1492, 2016.
PubMed
P.151 掲載の参考文献
1) Olafsson E, et al : Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification : a prospective study. Lancet Neurol 4 : 627-634, 2005.
PubMed
2) Leppik IE, Birnbaum AK : Epilepsy in the elderly. Ann NY Acad Sci 1184 : 208-224, 2010.
PubMed
3) Stefan H : Epilepsy in the elderly : facts and challenges. Acta Neurol Scand 124 : 223-237, 2011.
PubMed
4) Stefan H, et al : Epilepsy in the elderly : comparing clinical characteristics with younger patients. Acta Neurol Scand 129 : 283-293, 2014.
PubMed
5) Tanaka A, et al : Clinical characteristics and treatment responses in new-onset epilepsy in the elderly. Seizure 22 : 772-775, 2013.
PubMed
6) Hauser WA : Seizure disorders : the changes with age. Epilepsia 33 (Suppl 4) : S6-14, 1992.
 
7) McBride AE, et al : Video-EEG monitoring in the elderly : a review of 94 patients. Epilepsia 43 : 165-169, 2002.
PubMed
8) Drury I, Beydoun A : Interictal epileptiform activity in elderly patients with epilepsy. Electroencephalogr Clin Neurophysiol 106 : 369-373, 1998.
PubMed
9) 池田昭夫, 日本てんかん学会ガイドライン作成委員会 : 高齢者てんかんに対する診断・治療ガイドライン. てんかん研究 28 : 509-514, 2011.
 
10) Krumholz A, et al : Evidence-based guideline : Management of an unprovoked first seizure in adults : Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 85 : 1526-1527, 2015.
 
11) Leung T, et al : The prognosis of acute symptomatic seizures after ischaemic stroke. J Neurol Neurosurg Psychiatr 88 : 86-94, 2017.
 
12) 日本神経学会 (監), 「てんかん治療ガイドライン」作成委員会 (編) : てんかん治療ガイドライン 2010, 医学書院, 2010.
 
13) 橋本洋一郎 : 抗てんかん薬と抗凝固薬の併用-新規抗てんかん薬とNOACの活用-脳神経外科速報 25 : 56-61, 2015.
Medical*Online
P.158 掲載の参考文献
1) 日本老年医学会 : 高齢者の安全な薬物療法ガイドライン 2015. メジカルビュー, 2015.
 
2) By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel : American Geriatrics Society 2015 Updated Beers Criteria for Potentially lnappropriate Medication Use in Older Adults. J Am Geriatr Soc 63 : 2227-2246, 2015.
 
3) O'Mahony D, et al : STOPP/START criteria for potentially inappropriate prescribing in older people : version 2. Age Ageing 44 : 213-218, 2015.
PubMed
4) Gray SL, et al : Drug-induced cognition disorders in the elderly : incidence, prevention and management. Drug Saf 21 : 101-122, 1999.
PubMed
5) Gray SL, et al : Benzodiazepine use and risk of incident dementia or cognitive decline : prospective population based study. BMJ 352 : i90, 2016.
 
6) Dublin S, et al : Prescription Opioids and Risk of Dementia or Cognitive Decline : A Prospective Cohort Study. J Am Geriatr Soc 63 : 1519-1526, 2015.
 
7) カールソン神経科学-脳と行動-, 第4版 (泰羅雅登, 中村克樹監訳), 丸善出版, 2013.
 
8) Boustani M, et al : Impact of anticholinergics on the aging brain : a review and practical application. Aging Health 4 : 311-320, 2008.
 
9) Villalba-Moreno AM, et al : Anticholinergic risk : Use and limitations of anticholinergic scales. Eur J Intern Med 26 : e65-66, 2015.
PubMed
10) Villalba-Moreno AM, et al : Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr 62 : 1-8, 2016.
PubMed
11) Gray SL, et al : Cumulative use of strong anticholinergics and incident dementia : a prospective cohort study. JAMA Intern Med l75 : 401-407, 2015.
 
12) 篠原もえ子, 山田正仁 : 薬剤による認知機能障害. BRAIN and NERVE 64 : 1405-1410, 2012.
 
13) Tannenbaum C, et al : A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 29 : 639-658, 2012.
PubMed
14) Hanlon JT, et al : Histamine2 receptor antagonist use and decline in cognitive function among community dwelling elderly. Pharmacoepidemiol Drug Saf 13 : 781-787, 2004.
PubMed
15) Gray SL, et al : Histamine-2 receptor antagonist use and incident dementia in an older cohort. J Am Geriatr Soc 59 : 251-257, 2011.
 
16) Bassiony MM, et al : Cognitive Impairment and Tramadol Dependence. J Clin Psychopharmacol 37 : 61-66, 2017.
PubMed
17) Gomm W, et al : Association of Proton Pump Inhibitors With Risk of Dementia : A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol 73 : 410-416, 2016.
PubMed

IV 認知症予防

P.168 掲載の参考文献
1) Prince M, et al : World Alzheimer Report 2016-Improving healthcare for people living with dementia. Coverage, quality and costs now and in the future. Alzheimer's Disease International, London, 2016.
 
2) Ohara T, et al : Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology 88 : 1925-1932, 2017.
 
3) Satizabal CL, et al : Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med 374 : 523-532, 2016.
PubMed
4) Brookmeyer R, et al : Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3 : 186-191, 2007.
PubMed
5) Barnes DE, Yaffe K : The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10 : 819-828, 2011.
PubMed
6) Wilson RS, et al : Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 287 : 742-748, 2002.
PubMed
7) Bateman RJ, et al : Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 : 795-804, 2012.
PubMed
8) Selkoe DJ, Hardy J : The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8 : 595-608, 2016.
PubMed
9) Jonsson T, et al : Amutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488 : 96-99, 2012.
 
10) Matsuzaki T, et al : Insulin resistance is associated with the pathology of Alzheimer disease : the Hisayama study. Neurology 75 : 764-770, 2010.
PubMed
11) Arvanitakis Z, et al : Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people : a cross-sectional study. Lancet Neurol 15 : 934-943, 2016.
PubMed
12) Lazarov O, et al : Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120 : 701-713, 2005.
PubMed
13) Hannan AJ : Environmental enrichment and brain repair : harnessing the therapeutic effects of cognitive stimulation and physical activity to enhance experience-dependent plasticity. Neuropathol Appl Neurobiol 40 : 13-25, 2014.
PubMed
14) Duzel E, et al : Can physical exercise in old age improve memory and hippocampal function? Brain 139 : 662-673, 2016.
PubMed
15) Xie L, et al : Sleep drives metabolite clearance from the adult brain. Science 342 : 373-377, 2013.
PubMed
16) Kang JE, et al : Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326 : 1005-1007, 2009.
PubMed
17) Mander BA, et al : Sleep : A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? Trends Neurosci 39 : 552-566, 2016.
PubMed
18) Iwata N, et al : Metabolic regulation of brain Abeta by neprilysin. Science 292 : 1550-1552, 2001,
PubMed
19) Yasojima K, et al : Reduced neprilysin in high plaque areas of Alzheimer brain : a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 297 : 97-100, 2001.
 
20) Saito T, et al : Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 11 : 434-439, 2005.
PubMed
21) Ngandu T, et al : A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) : a randomised controlled trial. Lancet 385 : 2255-2263, 2015.
 
22) Saito T, et al : Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci 17 : 661-663, 2014.
PubMed
23) Sasaguri H, et al : APP mouse models for Alzheimer's disease preclinical studies. EMBO J 36 : 2473-2487, 2017.
PubMed
24) 井原康夫, 荒井啓行 : アルツハイマー病にならない! (朝日選書 827), 朝日新聞社, 2007.
 
P.173 掲載の参考文献
1) 浦上克哉, ほか : アルツハイマー型痴呆の遺伝子多型と簡易スクリーニング法. 老年精神医学雑誌 13 : 5-10, 2002.
Medical*Online
2) 斉藤潤, ほか : 認知症予防教室における対象者の判別法と評価法の検討. Dementia Japan 19 : 177-186, 2005.
 
3) Inoue M, Urakami K : Touch Panel-type Dementia Assessment Scale : anew computer-based rating scale for Alzheimer's disease. Psychogeriatrics 11 : 28-33, 2011.
 
4) Ito Y, Urakami K : Evaluation of dementia-prevention classes for community-dwelling older adults with mild cognitive impairment. Psychogeriatrics 12 : 3-10, 2012.
PubMed
5) Jimbo D, et al : Effect of aromatherapy on patients with Alzheimer's disease. Psychogeriatrics 9 : 173-179, 2009.
PubMed
P.180 掲載の参考文献
1) 佐渡充洋, ほか : 平成26年度厚生労働科学研究費補助金 (認知症対策総合研究事業) 総括研究報告書 「わが国における認知症の経済的影響に関する研究」, 2015.
 
2) Global Action Against Dementia Progress Report, distributed at 1st WHO Ministerial Conference on Global Action Against Dementia, 2015. 3. 16-17, Geneva.
 
3) Alzheimer's Disease International, World Alzheimer Report 2015 : The Global Impact of Dementia 2015. [https://www.alz.co.uk/research/world-report-2015] (2017年10月閲覧)
 
4) Alzheimer's Disease International, World Alzheimer Report 2010 : The Global Economic Impact of Dementia An analysis of prevalence, incidence, cost and trends. 2010. [https://www.alz.co.uk/research/world-report-2010] (2017年10月閲覧)
 
5) Wimo A, et al : The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 13 : 1-7, 2017.
PubMed
6) G8認知症サミット概要, 宣言, 共同声明 (日・英). [http://www.mhlw.go.jp/stf/houdou/0000033640.html] (2017年10月閲覧)
 
7) 認知症サミット日本後継イベントについて. [http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000058871.html] (2017年10月閲覧)
 
8) 認知症に対する世界的アクションに関する第1回WHO大臣級会合, CALL FOR ACTION (英語). [http://dementia.umin.jp/WHO_call-for-action2015.pdf] (2017年10月閲覧)
 
9) Ngandu T, et al : A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) : a randomised controlled trial. Lancet 385 : 2255-2263, 2015.
 
10) Pedersen JT, Sigurdsson EM : Tau immunotherapy for Alzheimer's disease. Trends Mol Med 21 : 394-402, 2015.
PubMed
11) 認知症サミットin Mie. [http://www.medic.mie-u.ac.jp/neurology/summit/] (2017年10月閲覧)
 
12) 神戸コミュニケ : G7神戸保健大臣会合, 2016年9月11日～12日. [http://www.mhlw.go.jp/seisakunitsuite/bunya/hokabunya/kokusai/g7kobe/KobeCommunique_a.pdf] (2017年10月閲覧)
 
P.187 掲載の参考文献
1) Ohara T, et al : Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology 88 : 1925-1932, 2017.
 
2) Ohara T, et al : Glucose tolerance status and risk of dementia in the community : the Hisayama study. Neurology 77 : 1126-1134, 2011.
PubMed
3) Ninomiya T, et al : Midlife and late-life blood pressure and dementia in Japanese elderly : the Hisayama study. Hypertension 58 : 22-28, 2011.
PubMed
4) Ohara T, et al : Midlife and late-life smoking and risk of dementia in the community : the Hisayama Study. J Am Geriatr Soc 63 : 2332-2339, 2015.
PubMed
5) Kishimoto H, et al : The long-term association between physical activity and risk of dementia in the community : the Hisayama Study. Eur J Epidemiol 31 : 267-274, 2016.
 
6) Aarsland D, et al : Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health 14 : 386-395, 2010.
PubMed
7) Hamer M, Chida Y : Physical activity and risk of neurodegenerative disease : a systematic review of prospective evidence. Psychol Med 39 : 3-11, 2009.
PubMed
8) Ozawa M, et al : Dietary patterns and risk of dementia in an elderly Japanese population : the Hisayama Study. Am J Clin Nutr 97 : 1076-1082, 2013.
 
9) Ozawa M, et al : Milk and dairy consumption and risk of dementia in an elderly Japanese population : the Hisayama Study. J Am Geriatr Soc 62 : 1224-1230, 2014.
 
P.194 掲載の参考文献
1) Hashimoto M, et al : Docosahexaenoic acid : one molecule diverse functions. Crit Rev Biotechnol 37 : 579-597, 2017.
PubMed
2) 橋本道男 : 食事-認知症予防の観点から-. 臨床精神医学 45 : 605-614, 2016.
Medical*Online
3) Gomez-Pinilla F : Brain foods : the effects of nutrients on brain function. Nat Rev Neurosci 9 : 568-578, 2008.
PubMed
4) Swaminathan A, Jicha GA : Nutrition and prevention of Alzheimer's dementia. Front Aging Neurosci 6, 2014. (doi : 10. 3389/fnagi. 2014. 00282)
 
5) Freund Levi Y, et al : Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease : the OmegAD study. J Intern Med 275 : 428-436, 2014.
PubMed
6) Tan ZS, et al : Red blood cell ω-3 fatty acid levels and markers of accelerated brain aging. Neurology 78 : 658-664, 2012.
 
7) Nguyen LN, et al : Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 509 : 503-506, 2014.
PubMed
8) Chen CT, et al : Plasma non-esterified docosahexaenoic acid is the major pool supplying the brain. Sci Rep 5 : 15791, 2015.
PubMed
9) Chen CT, et al : β-oxidation and rapid metabolism, but not uptake regulate brain eicosapentaenoic acid levels. Prostaglandins Leukot Essent Fatty Acids 92 : 33-40, 2015.
 
10) Belkouch M, et al : The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease. J Nutr Biochem 38 : 1-11, 2016.
PubMed
11) Zhang Y, et al : Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks : a dose-response meta-analysis of 21 cohort studies. Am J Clin Nutr 103 : 330-340, 2016.
PubMed
12) Jiao J, et al : Effect of n-3 PUFA supplementation on cognitive function throughout the life span from infancy to old age : a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 100 : 1422-1436, 2014.
 
13) Rijpma A, et al : The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease : results from a randomized controlled trial. Alzheimers Res Ther 9 : 51, 2017.
PubMed
14) Kondo T, et al : Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβand differential drug responsiveness. Cell Stem Cell 12 : 487-496, 2013.
 
15) Hashimoto M, et al : Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta 1738 : 91-98, 2005.
 
16) Heras-Sandoval D, et al : Role of docosahexaenoic acid in the modulation of glial cells in Alzheimer's disease. J Neuroinflammation 13 : 61, 2016.
PubMed
17) Conklin SM, et al : Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Neurosci Lett 421 : 209-212, 2007.
PubMed
18) Yanai H : Effects of N-3 Polyunsaturated Fatty Acids on Dementia. J Clin Med Res 9 : 1-9, 2017.
 
P.195 掲載の参考文献
19) Hashimoto M, et al : Neuroprotective and ameliorative actions of polyunsaturated fatty acids against neuronal diseases : beneficial effect of docosahexaenoic acid on cognitive decline in Alzheimer's disease. J Pharmacol Sci 116 : 150-162, 2011.
PubMed
P.200 掲載の参考文献
1) 山田正仁 : アルツハイマー病の診断と治療の新しい展開. からだの科学 278 : 2-7, 2013.
 
2) 小野賢二郎, 山田正仁 : 疾患修飾薬の開発研究の基礎. からだの科学 278 : 152-155, 2013.
 
3) Ono K, et al : Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro : implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 87 : 172-181, 2003.
PubMed
4) Ono K, Yamada M : Low-n oligomers as therapeutic targets of Alzheimer's disease. J Neurochem 117 : 19-28, 2011.
 
5) Orgogozo JM, et al : Wine consumption and dementia in the elderly : a prospective community study in the Bordeaux area. Rev Neurol (Paris) 153 : 185-192, 1997.
PubMed
6) Truelsen T, et al : Amount and type of alcohol and risk of dementia : the Copenhagen City Heart Study. Neurology 59 : 1313-1319, 2002.
PubMed
7) Ganguli M, et al : Apolipoprotein E polymorphism and Alzheimer disease : The Indo-US Cross-National Dementia Study. Arch Neurol 57 : 824-830, 2000.
PubMed
8) Kuriyama S, et al : Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan : the Ohsaki study. JAMA 296 : 1255-1265, 2006.
PubMed
9) Noguchi-Shinohara M, et al : Consumption of green tea, but not black tea or coffee, is associated with reduced risk of cognitive decline. PLoS ONE 9 : e96013, 2014.
PubMed
10) Ono K, et al : Effects of grape seed-derived polyphenols on amyloid β-protein self-assembly and cytotoxicity. J Biol Chem 283 : 32176-32187, 2008.
 
11) Ono K, et al : Phenolic compounds prevent amyloid β-protein oligomerization and synaptic dysfunction by site-specific binding. J Biol Chem 287 : 14631-14643, 2012.
 
12) Ehrnhoefer DE, et al : EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15 : 558-566, 2008.
PubMed
13) Wang J, et al : Grape-derived polyphenolics prevent Aβ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci 28 : 6388-6392, 2008.
 
14) Hamaguchi T, et al : Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-β aggregation pathway. Am J Pathol 175 : 2557-2565, 2009.
 
15) Noguchi-Shinohara M, et al : Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals : A Randomized Controlled Trial. PLoS ONE 10 : e0126422, 2015.
PubMed
P.206 掲載の参考文献
1) Suzuki T, et al : Effects of multicomponent exercise on cognitive function in older adults with amnestic mild cognitive impairment : a randomized controlled trial. BMC Neurol 12 : 128, 2012.
PubMed
2) Suzuki T, et al : A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One 8 : e61483, 2013.
 
3) Suzuki T, et al : Community-based intervention for prevention of dementia in Japan. J Prev Alz Dis 2 : 71-76, 2015.
 
4) Lin JS, et al : Screening for cognitive impairment in older adults : A systematic review for the U. S. Preventive Services Task Force. Ann Intern Med 159 : 601-612, 2013.
 
5) Ngandu T, et al : A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) : a randomised controlled trial. Lancet 385 : 2255-2263, 2015.
 
6) Matthews FE, et al : A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England : results of the Cognitive Function and Ageing Study I and II. Lancet 382 : 1405-1412, 2013.
 
7) Satizabal CL, et al : Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med 374 : 523-532, 2016.
PubMed
8) Langa KM, et al : A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Intern Med 177 : 51-58, 2017.
PubMed
9) Stern Y : What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 8 : 448-460, 2002.
PubMed
10) Kelaiditi E, et al : Cognitive frailty : rational and definition from an (I. A. N. A/I. A. G. G.) international consensus group. J Nutr Health Aging 17 : 726-734, 2013.
 
11) Snowdon DA, et al : Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 275 : 528-532, 1996.
PubMed
12) Stern Y, et al : Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 271 : 1004-1010, 1994.
PubMed
P.212 掲載の参考文献
1) Livingston G, et al : Dementia prevention, intervention, and care. Lancet, 2017. [Epub ahead of print]
 
2) Rolland Y, et al : Physical activity and Alzheimer's disease : from prevention to therapeutic perspectives. J Am Med Dir Assoc 9 : 390-405, 2008.
PubMed
3) NICE guideline. Dementia, disability and frailty in later life-mid-life approaches to delay or prevent onset, 2015. [https://www.nice.org.uk/guidance/ng16] (2017年9月閲覧)
 
4) Podewils LJ, et al : Physical activity, APOE genotype, and dementia risk : findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 161 : 639-651, 2005.
PubMed
5) Larson EB, et al : Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 144 : 73-81, 2006.
PubMed
6) Smith PJ, et al : Aerobic exercise and neurocognitive performance : a meta-analytic review of randomized controlled trials. Psychosom Med 72 : 239-252, 2010.
PubMed
7) Petersen RC, Morris JC : Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62 : 1160-1163 ; discussion 1167, 2005.
 
8) Ward A, et al : Mild cognitive impairment : disparity of incidence and prevalence estimates. Alzheimers Dement 8 : 14-21, 2012.
PubMed
9) Shimada H, et al : Combined prevalence of frailty and mild cognitive impairment in a population of elderly Japanese people. J Am Med Dir Assoc 14 : 518-524, 2013.
 
10) Mitchell AJ, Shiri-Feshki M : Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 119 : 252-265, 2009.
PubMed
11) Brodaty H, et al : Mild cognitive impairment in a community sample : the Sydney Memory and Ageing Study. Alzheimers Dement 9 : 310-317. e1, 2013.
 
12) Shimada H, et al : Conversion and Reversion Rates in Japanese Older People With Mild Cognitive Impairment. J Am Med Dir Assoc 18 : 808. e801-808. e806, 2017.
 
13) Plassman BL, et al : Systematic review : factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med 153 : 182-193, 2010.
PubMed

V アルツハイマー病治療薬開発

P.221 掲載の参考文献
1) 厚生労働省発表「日本における認知症の高齢者人口の将来推計に関する研究 (平成26年度厚生労働科学研究費補助金特別研究事業九州大学二宮利治教授)」
 
2) Alzheimer's Disease International. World Alzheimer Report 2016.
 
3) Cummings J, et al : Alzheimer's disease drug development pipeline : 2017. Alzheimer's & Dementia : Translational Research & Clinical Interventions 3 : 367-384, 2017.
PubMed
4) Jack CR, et al : Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9 : 119-128, 2010.
PubMed
5) Maruyama M, et al : Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 : 1094-1108, 2013.
 
6) Yang F, et al : Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280 : 5892-5901, 2005.
PubMed
7) Ma QL, et al : Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem 288 : 4056-4065, 2013.
PubMed
8) Anand P, et al : Bioavailability of curcumin : problems and promises. Mol Pharm 4 : 807-818, 2007.
PubMed
9) Brondino N, et al : Curcumin as a therapeutic agent in dementia : a mini systematic review of human studies. ScientificWorldJournal 2014, 2014. (doi : 10.1155/2014/174282)
 
P.229 掲載の参考文献
1) Hardy J, Selkoe DJ : The amyloid hypothesis of Alzheimer's disease : progress and problems on the road to therapeutics. Science 297 : 353-356, 2002.
PubMed
2) Gauthier S, et al : Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease : a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388 : 2873-2884, 2016.
PubMed
3) Frost B, Diamond MI : Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11 : 155-159, 2010.
PubMed
4) Bateman RJ, et al : Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 : 795-804, 2012.
PubMed
5) Farlow M, et al : Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 8 : 261-271, 2012.
PubMed
6) Doody RS, et al : Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 : 311-321, 2014.
PubMed
7) Sperling RA, et al : The A4 study : stopping AD before symptoms begin? Sci Transl Med 6 : 228fsl3, 2014.
PubMed
8) Bateman RJ, et al : The DIAN-TU Next Generation Alzheimer's prevention trial : Adaptive design and disease progression model. Alzheimers Dement 13 : 8-19, 2017.
PubMed
9) Food and Drug Administration : Guidance for lndustry-Alzheimer's Disease : Developing Drugs for the Treatment of Early Stage Disease. Draft Guidance, 2013. [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM338287.pdf]
 
P.236 掲載の参考文献
1) Hardy J, Selkoe DJ : The amyloid hypothesis of Alzheimer's disease : progress and problems on the road to therapeutics. Science 297 : 353-356, 2002.
PubMed
2) Bateman RJ, et al : Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 : 795-804, 2012.
PubMed
3) Schenk D, et al : Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 : 173-177, 1999.
PubMed
4) Gilman S, et al : Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 : 1553-1562, 2005.
 
5) Vellas B, et al : Long-term follow-up of patients immunized with AN1792 : reduced functional decline in antibody responders. Curr Alzheimer Res 6 : 144-151, 2009.
PubMed
6) Salloway S, et al : A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73 : 2061-2070, 2009.
PubMed
7) Salloway S, et al : Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 : 322-333, 2014.
PubMed
8) Siemers ER, et al : Phase 3 solanezumab trials : Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 12 : 110-120, 2016.
PubMed
9) Novakovic D, et al : Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug Des Devel Ther 7 : 1359-1364, 2013.
PubMed
10) Adolfsson O, et al : An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 32 : 9677-9689, 2012.
 
11) Sevigny J, et al : The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537 : 50-56, 2016.
 
12) Logovinsky V, et al : Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with aprotofibril selective Aβantibody. Alzheimers Res Ther 8 : 14, 2016.
 
13) Demattos RB, et al : A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron 76 : 908-920, 2012.
 
14) Takamura A, et al : Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse. Mol Neurodegener 6 : 20, 2011.
PubMed
15) Mills SM, et al : Preclinical trials in autosomal dominant AD : implementation of the DIAN-TU trial. Rev Neurol (Paris) 169 : 737-743, 2013.
PubMed
P.242 掲載の参考文献
1) Luo Y, et al : Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4 : 231-232, 2001.
PubMed
2) Zhao J, et al : Beta-site amyloid precursor protein cleaving enzyme l levels become elevated in neurons around amyloid plaques : implications for Alzheimer's disease pathogenesis. J Neurosci 27 : 3639-3649, 2007.
 
3) Yang LB, et al : Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9 : 3-4, 2003.
PubMed
4) Hardy J : A hundred years of Alzheimer's disease research. Neuron 52 : 3-13, 2006.
 
5) Jonsson T, et al : A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488 : 96-99, 2012.
 
6) Kennedy ME, et al : The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med 8 : 363ra150, 2016.
 
7) Evin G : Future Therapeutics in Alzheimer's Disease : Development Status of BACE Inhibitors. BioDrugs 30 : 173-194, 2016.
PubMed
8) Chou KC : Insights from modeling the tertiary structure of human BACE2. J Proteome Res 3 : 1069-1072, 2004.
PubMed
9) Willem M, et al : Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314 : 664-666, 2006.
PubMed
10) Hu X, et al : Bacel modulates myelination in the central and peripheral nervous system. Nat Neurosci 9 : 1520-1525, 2006.
 
11) Esterhazy D, et al : Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. Cell Metab 14 : 365-377, 2011.
 
12) Rochin L, et al : BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci USA 110 : 10658-10663, 2013.
PubMed
13) Shimshek DR, et al : Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMELI7 processing in mice. Sci Rep 6 : 21917, 2016.
 
14) May PC, et al : Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci 31 : 16507-16516, 2011.
 
15) Jack CR, et al : Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9 : 119-128, 2010.
PubMed

VI アルツハイマー病の先進医療とRegistry

P.252 掲載の参考文献
1) Jack CR, et al : Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9 : 119-128, 2010.
PubMed
2) Jack CR, et al : Tracking Pathophysiological processes in Alzheimer's disease : an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 : 207-216, 2013.
PubMed
3) Jack CR, et al : Serial PIB and MRI in normaL mild cognitive impairment and Alzheimer's disease : implications for sequence of pathological events in Alzheimer's disease. Brain 132 : 1355-1365, 2009.
PubMed
4) Mormino EC, et al : Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132 : 1310-1323, 2009.
PubMed
5) Lo RY, et al : Longitudinal change of biomarkers in cognitive decline. Arch Neurol 68 : 1257-1266, 2011.
PubMed
6) Jack CR, et al : Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 68 : 1526-1535, 2011.
PubMed
7) Vemuri P, et al : MRI and CSF biomarkers in normal, MCI, and AD subjects : predicting future clinical change. Neurology 73 : 294-301, 2009.
 
8) Vemuri P, et al : MRI and CSF biomarkers in normal, MCI, and AD subjects : diagnostic discrimination and cognitive correlations. Neurology 73 : 287-293, 2009.
 
9) Schuff N, et al : MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132 : 1067-1077, 2009.
PubMed
10) Jack CR, et al : Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133 : 3336-3348, 2010.
PubMed
11) Shaw LM, et al : Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 : 403-413, 2009.
 
12) De Meyer G, et al : Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67 : 949-956, 2010.
PubMed
13) Dubois B, et al : Advancing research diagnostic criteria for Alzheimer's disease : the IWG-2 criteria. Lancet Neurol 13 : 614-629, 2014.
PubMed
14) Kang JH, et al : The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core : A review of progress and plans. Alzheimers Dement 11 : 772-791, 2015.
 
15) Palmqvist S, et al : Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85 : 1240-1249, 2015.
PubMed
16) Toledo JB, et al : CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβin Alzheimer's disease. Acta Neuropathol 126 : 683-697, 2013.
 
17) Doecke JD, et al : Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69 : 1318-1325, 2012.
PubMed
18) O'Bryant SE, et al : A blood-based screening tool for Alzheimer's disease that spans serum and plasma : findings from TARC and ADNI, PLoS ONE 6 : e28092, 2011.
PubMed
19) Vemuri P, et al : Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67 : 308-316, 2010.
PubMed
20) Risacher SL, et al : Longitudinal MRI atrophy biomarkers : relationship to conversion in the ADNI cohort. Neurobiol Aging 31 : 1401-1418, 2010.
 
21) Spampinato MV, et al : Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology 258 : 843-852, 2011.
PubMed
22) Weiner MW, et al : 2014 Update of the Alzheimer's Disease Neuroimaging Initiative : A review of papers published since its inception. Alzheimers Dement 11 : el-120, 2015.
 
23) Weiner MW, et al : Recent publications from the Alzheimer's Disease Neuroimaging Initiative : Reviewing progress toward improved AD clinical trials. Alzheimers Dement 13 : e1-e85, 2017.
 
P.257 掲載の参考文献
1) Rowe CC, et al : Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31 : 1275-1283, 2010.
PubMed
2) Villemagne VL, et al : Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease : a prospective cohort study. Lancet Neurol 12 : 357-367, 2013.
 
3) Hedden T, et al : Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 80 : 1341-1348, 2013.
PubMed
4) Stonnington CM, et al : Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimers Dement 10 : e1-8, 2014.
PubMed
5) Jack CR, et al : Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9 : 119-128, 2010.
PubMed
6) Donohue MC, et al : The preclinical Alzheimer cognitive composite : measuring amyloid-related decline. JAMA Neurol 71 : 961-970, 2014.
PubMed
7) Doody RS, et al : Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 : 311-321, 2014.
PubMed
P.265 掲載の参考文献
1) Bateman RJ, et al : Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 : 795-804, 2012.
PubMed
2) Perrin RJ, et al : Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461 : 916-922, 2009.
PubMed
3) Cruchaga C, et al : Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 7 : e31039, 2012.
PubMed
4) Lopera F, et al : Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 277 : 793-799, 1997.
 
5) 森啓 : 家族性アルツハイマー病の人及びその家族に対する支援体制に関する調査研究事業. 平成25年度老人保健事業推進費等補助金・老人保健健康増進等事業報告書. 2014年3月.
 
6) 森啓, ほか : Dominantly Inherited Alzheimer's Network (DIAN) について. Dementia Japan 28 : 116-126, 2014.
 
7) 嶋川裕之 : DIAN family conference in AAIC 2016. Brain and Nerve 69 : 178-180, 2016.
 
P.271 掲載の参考文献
1) Bateman RJ, et al : Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 : 795-804, 2012.
PubMed
2) Klunk WE, et al : Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 : 306-319, 2004.
PubMed
3) Ewers M, et al : CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 22 : 1993-2004, 2012.
PubMed
4) Villemagne VL, et al : Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69 : 181-192, 2011.
 
5) Morris JC, et al : APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67 : 122-131, 2010.
 
6) Chetelat G, et al : Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 78 : 477-484, 2012.
 
7) Pike KE, et al : Cognition and beta-amyloid in preclinical Alzheimer's disease : data from the AIBL study. Neuropsychologia 49 : 2384-2390, 2011.
PubMed
8) Kantarci K, et al : APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology 78 : 232-240, 2012.
 
9) Sperling RA, et al : Toward defining the preclinical stages of Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 : 280-292, 2011.
PubMed
P.277 掲載の参考文献
1) World Alzheimer Report 2015. The Global Impact of Dementia. [https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf] (2017年10月閲覧)
 
2) Livingston G, et al : Dementia prevention, intervention, and care. Lancet pii : S0140-6736 (17) 31363-6, 2017. [Epub ahead of print]
 
3) Welcome to European Prevention of Alzheimer's Dementia Consortium (EPAD). [http://ep-ad.org/] (2017年10月閲覧)
 
4) Welcome to the Global Alzheimer's Platform (GAP) Foundation. [http://globalalzplatformorg/] (2017年10月閲覧)
 
5) The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). [https : //aibl.csiro.au/] (2017年10月閲覧)
 
6) Sakurai T, et al : Japan's challenge of early detection of persons with cognitive decline. J Am Med Dir Assoc 17 : 451-452, 2016.
PubMed
7) Saji N, et al : ORANGE's challenge : developing wide-ranging dementia research in Japan. Lancet Neurol 15 : 661-662, 2016.
 

VII 新たな視点・問題点

P.286 掲載の参考文献
1) Furukawa K, et al : Exacerbation of dementia after the earthquake and tsunami in Japan. J Neurol 259 : 1243, 2012.
PubMed
2) Ikejima C, et al : Multicentre population-based dementia prevalence survey in Japan : apreliminary report. Psychogeriatrics 12 : 120-123, 2012.
 
3) Daito H, et al : Impact of the Tohoku earthquake and tsunami on pneumonia hospitalisations and mortality among adults in northern Miyagi, Japan : a multicentre observational study. Thorax 68 : 544-550, 2013.
PubMed
4) 冲永壯治, ほか : 大災害時における高齢者救急医療. 日本臨牀 71 : 1097-1102, 2013.
Medical*Online
5) Yamanda S, et al : The impact of the 2011 Great East Japan Earthquake on hospitalisation for respiratory disease in a rapidly aging society : a retrospective descriptive and cross-sectional study at the disaster base hospital in Ishinomaki. BMJ Open 3 : e000865, 2013.
 
6) Takahashi H, et al : Pneumonia after earthquake, Japan, 2011. Emerging Infect Dis 18 : 1909-1911, 2012.
 
7) Ishiki A, et al : Changes in Cognitive Functions in the Elderly Living in Temporary Housing after the Great East Japan Earthquake. PLoS One 11 : e0147025, 2016.
PubMed
8) Sewo Sampaio PY, et al : Systematic review of the Kihon Checklist : Is it a reliable assessment of frailty? Geriatr Gerontol Int 16 : 893-902, 2016.
PubMed
9) 冲永壯治, ほか : 災害時における高齢者の救済-東日本大震災の時系列と今後の課題-. 日本老年医学会雑誌 54 : 136-142, 2017.
 
10) 石川和信 : 福島第一原発事故6年後の被災高齢者の現状と問題点. 日本老年医学会雑誌 54 : 129-135, 2017.
 
P.292 掲載の参考文献
1) Michon JA : A critical view of driver behavior models : What do we know, what should we do? In : Human Behavior and Traffic Safety, Proceedings of a General Motors Symposium on Human Behavior and Traiiffic Safety, Plenum Press, New York, 1985.
 
2) Eby DW, et al : Maintaining Safe Mobility in an Aging Society. CRC Press, Boca Raton, 2009.
 
3) Carr DB, Ott BR : The older adult driver with cognitive impairment : "It's a very frustrating life". JAMA 303 : 1632-1641, 2010.
 
4) Walter H, et al : The neural correlates of driving. Neuroreport 12 : 1763-1767, 2001.
PubMed
5) Horikawa E, et al : The neural correlates of driving perfOrmance identified using PET. Brain Cogn 58 : 166-171, 2005.
 
6) 渡邉修ほか : 脳損傷者の自動車運転中の脳血流動態-機能的近赤外分光法による計測-, 日本職業・災害医学学会誌 59 : 238-244, 2011.
 
7) Jeong M, et al : Functional brain mapping of actual car-driving using [18F] FDG-PET. Ann Nucl Med 20 : 623-628, 2006.
PubMed
8) Elkin-Frankston S, et al : The use of the Color Trails Test in the assessment of driver competence : Preliminary report of a culture-fair instrument. Arch Clin Neuropsychol 22 : 631-635, 2007.
PubMed
9) Horikawa, et al : Elderly driving behavior and cognitive functions : Analysis of license renewal course data. IATSS Research 33 : 18-26, 2009.
 
10) Bliokas VV, et al : Neuropsychological assessment of fitness to drive following acquired cognitive impairment. Brain Inj 25 : 471-487, 2011.
PubMed
11) Freund B, et al : In my car the brake is on the right : pedal errors among older drivers. Accid Anal Prev 40 : 403-409, 2008.
 
12) Ott BR et al : Naturalistic validation of an on-road driving test of older drivers. Hum Factors 54 : 663-674, 2012.
 
13) Davis JD, et al : Road test and naturistic driving Performance in healthy and cognitively impaired older adults : does environment matter? J Am Geriatr Soc 60 : 2056-2062, 2012.
 
14) O'Connor ML, et al : Self-rated driving habits among older adults with clinically-defined mild cognitive impairment, clinically-defined dementia, and normal cognition. Accid Anal Prev 61 : 197-202, 2013.
PubMed
15) Classen S, et al : Item development and validity testing for a self・-and proxy report : the safe driving behavior measure. Am J Occup Ther 64 : 296-305, 2010.
 
16) 堀川悦夫, ほか : 「認知症及び認知機能低下高齢者の運転に関するご家族による評価尺度日本語版の作成」, Dement Jpn 29 : 416, 2015.
 
17) Piersma D, et al : Prediction of fitness to drive in patients with Alzheimer's dementia. PLos One 11, 2016. (doi : 10. 1371/journal. pone. 0149566)
 
P.298 掲載の参考文献
1) Cheng G, et al : Diabetes as a risk factor for dementia and mild cognitive impairment : a meta-analysis of longitudinal studies. Intern Med J 42 : 484-491, 2012.
PubMed
2) Ma F, et al : Conversion of mild cognitive impairment to dementia among subjects with diabetes : a population-based study of incidence and risk factors with five years of follow-up. J Alzheimers Dis 43 : 1441-1449, 2015.
PubMed
3) Palta P, et al : Magnitude of cognitive dysfunction in adults with type 2 diabetes : a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. J Int Neuropsychol Soc 20 : 278-291, 2014.
PubMed
4) Alagiakrishnan K, et al : Montreal Cognitive Assessment is superior to Standardized Mini-Mental Status Exam in detecting mild cognitive impairment in the middle-aged and elderly patients with type 2 diabetes mellitus. Biomed Res Int 2013, 2013. (doi : 10. 1155/2013/186106)
 
5) Crane PK, et al : Glucose levels and risk of dementia. N Engl J Med 369 : 540-548, 2013.
PubMed
6) Umegaki H, et al : Risk factors associated with cognitive decline in the elderly with type 2 diabetes : pooled logistic analysis of a 6-year observation in the Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int 12 (Suppl 1) : 110-116, 2012.
 
7) Mattishent K, Loke YK : Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents : asystematic review and meta-analysis. Diabetes Obes Metab 18 : 135-141, 2016.
 
8) Rawlings AM, et al : Glucose Peaks and the Risk of Dementia and 20-Year Cognitive Decline, Diabetes Care 40 : 879-886, 2017.
PubMed
9) Haroon NN, et al : Risk of dementia in seniors with newly diagnosed diabetes : apopulation-based study. Diabetes Care 38 : 1868-1875, 2015.
 
10) Araki A, et al ; Japanese Elderly Diabetes Intervention Trial Research Group : Low intakes of carotene, vitamin B2, pantothenate and calcium predict cognitive decline among elderly patients with diabetes mellitus : The Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int 17 : 1168-1175, 2017.
 
11) Beckett MW, et al : A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer's disease in older adults. BMC Geriatr 15 : 9, 2015.
PubMed
12) Bruce DG, et al : Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia 51 : 241-248, 2008.
PubMed
13) Espeland MA, et al : Effects of Physical Activity Intervention on Physical and Cognitive Function in Sedentary Adults With and Without Diabetes. J Gerontol A Biol Sci Med Sci 72 : 861-866, 2017.
PubMed
14) Gillette Guyonnet S, et al : IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging 11 : 132-152, 2007.
PubMed
15) Devore EE, et al. Dietary fat intake and cognitive decline in women with type 2 diabetes. Diabetes Care 32 : 635-640, 2009.
PubMed
16) Scarmeas N, et al : Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 59 : 912-921, 2006.
PubMed
17) Volkert D, et al : ESPEN guidelines on nutrition in dementia. Clin Nutr 34 : 1052-1073, 2015.
PubMed
18) Feil DG, et al : Risk of hypoglycemia in older veterans with dementia and cognitive impairment : implications for practice and policy. J Am Geriatr Soc 59 : 2263-2272, 2011.
 
19) McCoy RG, et al : Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Intern Med 176 : 969-978, 2016.
PubMed
20) 糖尿病治療ガイド 2016-2017 (日本糖尿病学会編・著), p97-98, 文光堂, 2016.
 
P.304 掲載の参考文献
1) Fried LP, et al : Frailty in older adults : evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56 : M146-156, 2001.
PubMed
2) Cruz-Jentoft AJ, et al : Sarcopenia : European consensus on definition and diagnosis : Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39 : 412-423, 2010.
 
3) Verghese J, et al : Motoric cognitive risk syndrome : multicountry prevalence and dementia risk. Neurology 83 : 718-726, 2014.
PubMed
4) Kelaiditi E, et al : Cognitive frailty : rational and definition from an (I. A. N. A. /I. A. G. G.) international consensus group. J Nutr Health Aging 17 : 726-734, 2013.
 
5) Kojima G, et al : Prevalence of frailty in Japan : A systematic review and meta-analysis. J Epidemiol 27 : 347-353, 2017.
PubMed
6) Livingston G, et al : Dementia prevention, intervention, and care. Lancet, 2017. [Epub ahead of print]
 
7) Derby CA, et al : Trends in Dementia Incidence in a Birth Cohort Analysis of the Einstein Aging Study. JAMA Neurol, 2017. [Epub ahead of print]
 
8) Ahmadi-Abhari S, et al : Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040 : modelling study. BMJ 358, 2017. (doi : 10. 1136/bmj. j2856)
 
9) Xue QL, et al : Initial manifestations of frailty criteria and the development of frailty phenotype in the Women's Health and Aging Study II. J Gerontol A Biol Sci Med Sci 63 : 984-990, 2008.
 
10) Chen LK, et al : Sarcopenia in Asia : consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15 : 95-101, 2014.
 
11) Chan DC, et al : A pilot randomized controlled trial to improve geriatric frailty. BMC Geriatr 12 : 58, 2012.
PubMed
12) Talbot LA, et al : A home-based pedometer-driven walking program to increase physical activity in older adults with osteoarthritis of the knee : a preliminary study. J Am Geriatr Soc 51 : 387-392, 2003.
PubMed
13) Ngandu T, et al : A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) : a randomised controlled trial. Lancet 385 : 2255-2263, 2015.
 
14) Kobayashi S, et al : High protein intake is associated with low prevalence of frailty among old Japanese women : a multicenter cross-sectional study. Nutr J 12 : 164, 2013.
PubMed
15) Bollwein J, et al : Dietary quality is related to frailty in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 68 : 483-489, 2013.
PubMed
P.309 掲載の参考文献
1) 国立社会保障・人口問題研究所 日本の将来推計人口 (平成18年12月推計), 2006.
 
2) 猪飼周平 : 病院の世紀の理論, 有斐閣, 2010.
 
P.315 掲載の参考文献
1) Chalmers JM, et al : Caries incidence and increments in community-living older adults with and without dementia. Gerodontology 19 : 80-94, 2002.
 
2) Ellefsen B, et al : Assessing caries increments in elderly patients with and without dementia : a one-year follow-up study. J Am Dent Assoc 140 : 1392-1400, 2009,
PubMed
3) Taji T, et al : Influence of mental status on removable prosthesis compliance in institutionalized elderly persons. Int J prosthodont 18 : 146-149, 2005.
PubMed
4) Poukkula A, et al : Long-term presence of a denture fragment in the airway (a report of two cases). JLaryngol Otol 102 : 190-193, 1988.
PubMed
5) Stein PS, et al : Tooth loss, dementia and neuropathology in the Nun study. J Am Dent Assoc 138 : 1314-1322 ; quiz 1381-1382, 2007.
 
6) Batty GD, et al : Oral disease in relation to future risk of dementia and cognitive decline : prospective cohort study based on the Action in Diabetes and Vascular Disease : Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. Eur Psychiatry 28 : 49-52, 2013.
PubMed
7) Sparks Stein P, et al : Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement 8 : 196-203, 2012.
PubMed
8) Ide M, et al : Periodontitis and Cognitive Decline in Alzheimer's Disease. PLoS ONE 11 : e0151081, 2016.
PubMed
9) Kikutani T, et al : Effect of oral care on cognitive function in patients with dementia. Geriatr Gerontol Int 10 : 327-328, 2010.
PubMed
P.320 掲載の参考文献
1) 臺有桂, ほか (編) : 在宅看護とは. ナーシング・グラフィカ在宅看護論 : 地域療養を支えるケア, p19, メディカ出版, 2014.
 
2) 厚生労働省 : 認知症施策の現状について. [http://wwwmhlw.go.jp/file/05-Shingikai-12601000-Seisakutoukatsukan-Sanjikanshitsu_Shakaihoshoutantou/0000065682.pdf] (2017年11月閲覧)
 
3) 厚生労働省ほか : 認知症施策推進総合戦略 (新オレンジプラン). [http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000064084.html] (2017年11月閲覧)
 
4) 日本医療福祉生活協同組合連合会 : 平成24-25年度認知症の生活支援実態と支援方策の開発に関する臨床研究事業報告書, 2013.
 
5) 厚生労働省 : 平成25年度介護サービス施設・事業所調査, 訪問看護ステーションの利用者における傷病別の割合, 2013.
 
6) 厚生労働省 : 平成25年度介護サービス施設・事業所調査, 2013.
 
7) 厚生労働省 : 平成26年国民生活基礎調査, 2014.
 
8) Tom Kitwood : Dementia Reconsidered : The Person Comes First, Open University Press, p107-143, 1997.
 
9) 上田敏 : ICF (国際生活機能分類) の理解と活用, p28-29, きょうされん, 2005.
 
10) 安武 綾ほか : 認知症高齢者の家族の体験 症状発現から診断まで. 老年看護学 12 : 32-39, 2007.
Medical*Online
11) 厚生労働省 : 平成25年度高齢者虐待の防止, 高齢者の養護者に対する支援等に関する法律に基づく対応状況等に関する調査結果, 2015.
 
12) 安武綾 : 認知症患者を介護している家族の体験のメタ統合. 家族看護学研究 17 : 2-12, 2011.
Medical*Online
13) 安武綾 : 在宅で生活する認知症高齢者家族のソーシャルサポート尺度の開発, 2016年度聖路加国際大学大学院博士論文, p33-44, 2016.
 
14) Monahan DJ, et al : Health of spouse caregivers of dementia patients : the role of personality and social support. Soc Work 40 : 305-314, 1995.
 
15) Adams KB : The transition to caregiving : the experience of family members embarking on the dementia caregiving career. J Gerontol Soc Work 47 : 3-29, 2006.
PubMed
16) Gottlieb BH, ほか (編) : ソーシャルサポートの測定と介入 (小杉正太郎, ほか訳), p39-40, 川島書店, 2005.
 
17) 西山みどり : ともに暮らす高齢者の認知症発症に伴う主介護者の生活再編成. 老年看護学 9 : 85-91, 2004.
 
18) Au A, et al : Social support and well-being in dementia family caregivers : the mediating role of self-efficacy. Aging Ment Health 13 : 761-768, 2009.
PubMed
P.325 掲載の参考文献
1) 認知症介護情報ネットワーク [http://www.dcnet.gr.jp/] (2017年11月閲覧)
 
2) 荒井由美子, ほか : Zarit介護負担尺度日本語版の短縮版 (J-ZBI_8) の作成 ; その信頼性と妥当性に関する検討. 日本老年医学会雑誌 40 : 497-503, 2003.
 
3) 本間昭, 大塚俊男監修 : 高齢者のための知的機能検査の手引き. ワールドプランニング, 1991.
 
4) International Psychogeriatric Association : Behavioral and Psychological Symptoms of Dementia ; Educational Pack, 2nd ed, lnternational Psychogeriatric Association, Skokie, 2003. 日本老年精神医学会監訳 : 認知症の行動と心理症状BPSD, 第2版, アルタ出版, 東京, 2013.
 
5) Reisberg B, et al : Behavioral symptoms in Alzheimer's disease : Phenomenology and treatment. J Clin Psychiatry 48 (Suppl) : 9-15, 1987.
 
6) Cummings JL, et al : The Neuropsychiatric Inventory : comprehensive assessment of psychopathology in dementia. Neurology 44 : 2308-2314, 1994.
PubMed
7) Lawton MP, et al : Observed affect in nursing home residents with Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci 51 : 3-14, 1996.
 
8) Logsdon RG, Teri L : The Pleasant Events Schedule-AD : psychometric properties and relationship to depression and cognition in Alzheimer's disease patients. Gerontologist 37 : 40-45, 1997.
PubMed
9) Brod M, et al : Conceptualization and measurement of quality of life in dementia : the dementia quality of life instrument (DQoL). Gerontologist 39 : 25-35, 1999.
PubMed
10) 鈴木みずえ, ほか : 日本語版Dementia Quality of Life Instrumentの作成と信頼性・妥当性の検討. 日本老年医学会雑誌 42 : 423-431, 2005.
 
11) 鈴木みずえ, ほか : 日本語版Dementia Quality of Life Instrument (DQoL-Japanese Version) を用いた認知症高齢者の主観的Quality of Lifeに関する縦断評価. 日本老年医学会雑誌 43 : 485-491, 2006.
 
12) キャサリン・ポープ, ほか : 質的研究と量的研究のエビデンスの統合 ; ヘルスケアにおける研究・実践・政策への活用, 医学書院 2009.
 
13) 日本神経学会監修 : 認知症疾患診療ガイドライン 2017, 医学書院, 2017.
 
14) 中村考一 : 認知症ケアレジストリ研究 ; BPSDスポット調査を中心に. 日本老年精神医学雑誌 28 : 1091-1096, 2017.
 

VIII 専門職の養成強化

P.332 掲載の参考文献
1) 一般社団法人・日本神経学会 [https://www.neurology-jp.org/] (2017年10月閲覧)
 
2) 認知症疾患診療ガイドライン 2017 (日本神経学会 (監修), 認知症疾患診療ガイドライン作成委員会 (編集)), 医学書院, 2017.
 
3) 日本神経学会 : 神経疾患克服に向けた研究推進の提言 2016, 2016. [https://www.neurology-jp.org/images/teigen_2016.pdf] (2017年10月閲覧)
 
4) 文部科学省・課題解決型高度医療人材養成プログラム「北陸認知症プロフェッショナル医養成プラン」 (認プロ) [http://ninpro.jp] (2017年10月閲覧)
 
P.338 掲載の参考文献
1) 日本老年医学会ホームページ [http://www.jpn-geriat-soc.or.jp/senmoni/index.html] (2017年11月閲覧)
 
P.343 掲載の参考文献
1) 認知症疾患診療ガイドライン 2017 (認知症疾患診療ガイドライン作成委員会編, 日本神経学会監修), p170-201, 医学書院, 2017.
 
2) 認知症テキストブック (日本認知症学会編), 中外医学社, 2008.
 
P.346 掲載の参考文献
1) 改訂・老年精神医学講座 ; 総論, 日本老年精神医学会編, ワールドプランニング, 2009.
 
2) 改訂・老年精神医学講座 ; 各論, 日本老年精神医学会編, ワールドプランニング, 2009.
 
P.350 掲載の参考文献
1) 厚生労働省ホームページ : G8認知症サミットディクラレーション (宣言), 2013. [http://www.mhlw.go.jp/file/04-Houdouhappyou-10501000-Daijinkanboukokusaika-Kokusaika/0000033637.pdf] (2017年10月閲覧)
 
2) 日本認知症予防学会ホームページ : 認知症予防専門医 [http://ninchishou.jp/index.php?id=75] (2017年10月閲覧)
 
3) Bateman RJ, et al : Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 : 795-804, 2012.
PubMed
4) Barnes DE, et al : The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10 : 819-828, 2011.
PubMed
5) 日本認知症予防学会ホームページ : エビデンス創出委員会. [http://ninchishou.jp/index.php?id=72] (2017年10月閲覧)
 
P.355 掲載の参考文献
1) 厚生労働省 : 平成28年国民生活基礎調査の概況. [http://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa16/dl/02.pdf] (2017年7月閲覧)
 
2) 三輪のり子, 金原京子 : ゆとり世代の看護学生における高齢者観の特徴. 老年看護学 19 : 47-57, 2015.
Medical*Online
3) 公益社団法人日本看護協会 : 専門看護師・認定看護師・認定看護管理者. [http://nintei.nurse.or.jp/nursing/qualification/about_institution] (2017年7月閲覧)
 
4) 坂本すが : 日本看護協会における認知症ケア充実への取り組み. 老年看護学 20 : 26-30, 2015.
Medical*Online
5) 厚生労働省 : 中央社会保険医療協議会第315回総会. [http://wwwmhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000105049.pdf] (2017年7月閲覧)
 
6) 日本学術会議 : 超高齢社会のフロントランナー日本 : これからの日本の医学・医療のあり方. [http://www.jpn-geriat-soc.or.jp/info/topics/pdf/20141014_01_Ol.pdf] (2017年7月閲覧)
 
7) 日本老年医学会 : 高齢者に対する適切な医療提供の指針. [http://www.jpn-geriat-soc.or.jp/proposal/pdf/geriatric_care_GL.pdf] (2017年7月閲覧)
 
8) Trevor A, Clark CL編, 神郡博, 竹花富子監訳 : 認知症の人々へのケア-パートナーシップに基づく新しい知識, 日本看護協会出版会, 2006.
 
9) 中島紀恵子, ほか編 : 認知症の人々の看護, 医歯薬出版, 2013.
 
P.360 掲載の参考文献
1) 平成27年度 歯科医師, 薬剤師, 看護師および急性期病棟従事者等への認知症対応力向上研修教材開発に関する研究事業 (厚生労働省老人保健健康増進等事業) : かかりつけ医認知症対応力向上研修テキスト, 2016. [http://ham-ken.com/wp/wp-content/uploads/2016/06/eaa81f5830155183692f38cb26e77c47.pdf] (2017年11月閲覧)
 
2) 平成27年度 歯科医師, 薬剤師, 看護師および急性期病棟従事者等への認知症対応力向上研修教材開発に関する研究事業 (厚生労働省老人保健健康増進等事業) : 薬剤師認知症対応力向上研修テキスト, 2016, [http://ham-ken.com/wp/wp-content/uploads/2016/06/fc2bOld923b587ff80db62786885ee40.pdf] (2017年11月閲覧)
 
3) 山浦克典, ほか : 超簡単!! 論文作成ガイド～『研究』しよう～, 薬事日報社, 2016.
 
P.368 掲載の参考文献
1) 浦上克哉 : 認知症医療における臨床検査技師の役割. Medical Technology 41 : 252-255, 2013.
Medical*Online
2) 日本認知症予防学会 (監), 浦上克哉, 児玉直樹 (編) : 認知症予防専門士テキストブック, メディケアプラス, 2013.
 
3) 日本臨床衛生検査技師会 (監) : JAMT教本シリーズ 超音波検査技術教本, じほう, 2015.
 
4) 日本臨床衛生検査技師会 (監) : JAMT教本シリーズ 神経生理検査事例集, じほう, 2015.
 
5) 日本臨床衛生検査技師会 (監) : 医学検査別冊「認知症予防のための検査」特集号, 2017.
 
6) 深澤恵治 : 臨床検査技師のかかわり 認定認知症領域検査技師の現状と課題. 臨床検査 41 : 1538-1544, 2016.
 
P.375 掲載の参考文献
1) 新オレンジプラン [http://wwwmhlw.go.jp/stf/houdou/0000072246.html] (2017年8月閲覧)
 
2) 一般社団法人日本認知症ケア学会HP (全体像) [http://184.73.219.23/d_care/senmonsi/2017/senmonsi_seido.htm] (2017年8月閲覧). 一般社団法人日本認知症ケア学会HP (制度規則, 試行細則) [http://184.73.219.23/d_care/senmonsi/2016/seido_kisoku.htm] (2017年8月閲覧). 一般社団法人日本認知症ケア学会HP (制度の流れ, 教育プログラム) [http://184.73.219.23/d_care/senmonsi/2017/seido_nagare.htm] (2017年8月閲覧).
 
3) 日本認知症ケア学会 : 認知症ケア専門士制度がケア現場にもたらした効果の検証研究事業報告書. 「平成21年度老人保健推進費等補助金 (老人保健健康増進等事業分) 報告書」, 認知症ケア事例ジャーナル 3 : 312-318, 2010-2012.
 
4) 笹賀美代子 : 認知症ケア専門士の活動実態が仕事満足感や自尊感情に及ぼす影響. 日本認知症ケア学会誌 15 : 457-469, 2016.
Medical*Online
5) 日本認知症ケア学会・認知症ケア専門士認定委員会委員長長田久雄 : 認知症ケア専門士になろう! ケアマネジメント 21 : 32-33, 2010.
 
6) 今井幸充 : 認知症ケア学会認定認知症ケア専門士に期待されるものと今後の課題-認知症ケアの標準化を目指して. 老年精神医学雑誌 19, 650-656, 200 &
 
7) 今井幸充 : 日本認知症ケア学会の立場からの教育の現状と課題. 老年精神医学雑誌 21 : 1108-1115, 2010.
Medical*Online
P.380 掲載の参考文献
1) 厚生労働省ホームページ「認知症施策推進総合戦略～認知症高齢者等にやさしい地域づくりに向けて～ (新オレンジプラン) 」について. [http://www.mhlw.go.jp/stf/houdou/0000072246.html] (2017年7月閲覧)
 
2) 厚生労働省ホームページ : 第6回認知症高齢者等にやさしい地域づくりに係る関係省庁連絡会議 (平成29年7月5日) 資料1 認知症施策推進総合戦略 (新オレンジプラン) の数値目標の更新等について. [http://www.mhlw.go.jp/file/05-Shingikai-12301000-Roukenkyoku-Soumuka/0000146425_2.pdf] (2017年7月閲覧)
 
3) 厚生労働省ホームページ : 地域支援事業の充実と介護予防の見直し 2014. [http://wwwmhlw.go.jp/file/05-Shingikai-12301000-Roukenkyoku-Soumuka/0000044833.pdf] (2017年7月閲覧)
 
4) 鷲見幸彦 : 認知症サポート医. 医学のあゆみ 224 : 166-168, 2008.
Medical*Online
5) 鷲見幸彦 : 認知症学 (下) -その解明と治療の最新知見-, サポート医と介護研修. 日本臨牀 69 (増刊号10) : 561-564, 2011.
 
6) Washimi Y, et al : Educational program in Japan for Dementia Support Doctors who support medical and care systems as liaisons for demented older adults in the community. Geriatr Gerontol Int 14 (Suppl 2) : 11-16, 2014.
 
7) ニッセイ基礎研究所 : 認知症サポート医等のあり方および研修体系・教材に関する研究事業. 事業報告書, p36-39, ニッセイ基礎研究所, 2013.
 
8) 粟田主一 : 診療所医師の機能-認知症地域医療支援事業の意義について-. 老年医学 151 : 35-38, 2013.
 
9) 伊古田俊夫 : 講談社ブルーバックス「脳からみた認知症」, p224-235, 講談社, 2012.
 
10) 財団法人 日本公衆衛生協会 : 認知症患者の増加に対応したかかりつけ医の対応力向上研修のあり方に関する研究会報告書, p3, 2004.
 
11) 富士通総研 : 循環型による認知症の医療・介護等の提供のあり方に関する調査研究事業. 事業報告書, p52-59, 2017.
 
12) 鷲見幸彦 : ポータルサイト「認知症サポート医ネットワーク」を創設Medical Tribune 45 : 19, 2012.
 
13) 認知症サポート医ネットワーク. [https://www.dsd-network.jp/] (2017年7月閲覧)
 
P.384 掲載の参考文献
1) Kojima T, et al : High risk of adverse drug reactions in elderly patients taking six or more drugs : analysis of inpatient database. Geriatr Gerontol Int 12 : 761-762, 2012.
PubMed
P.386 掲載の参考文献
1) 日本老年医学会 : 高齢者に対する適切な医療提供の指針, 2010. [https://www.jpn-geriat-soc.or.jp/proposal/pdf/geriatric_care_GL.pdf.] (2017年11月閲覧)
 
2) 全国老人保健施設協会 : 介護老人保健施設の管理医師の有効活用による医療と介護の連携の促進に関する調査研究事業, 2014. [http://www.roken.or.jp/wp/wp-content/uploads/2012/07/H26_kanri_ishi.pdf] (2017年11月閲覧)
 
P.392 掲載の参考文献
1) 内閣府, 平成28年版高齢社会白書. [http://www8.cao.go.jp/kourei/whitepaper/w-2016/html/zenbun/index.html] (2017年8月閲覧)
 
2) 古田光, ほか : 一般病床高齢者入院患者における認知症実態調査の試み 総合病院精神医学会認知症委員会多施設共同研究. 総合病院精神医学 27 : 100-106, 2015.
 
3) Reynish EL, et al : Epidemiology and outcomes of people with dementia, delirium, and unspecified cognitive impairment in the general hospital : prospective cohort study of 10,014 admissions. BMC Med 15 : 140, 2017.
PubMed
4) Bergeron N, et al : Intensive Care Delirium Screening Checklist : evaluation of a new screening tool. Intensive Care Med 27 : 859-864, 2001.
PubMed
5) 武田章敬 : わが国の認知症施策の未来 身体救急疾患をきたした認知症の人の支援体制を整備するために. 老年精神医学雑誌 28 : 189-195, 2017.
 
6) LaMantia MA, et al : Emergency Department Use Among Older Adults With Dementia. Alzheimer Dis Assoc Disord 30 : 35-40, 2016.
PubMed
7) National Comprehensive Cancer Network. [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp] (2017年8月閲覧)
 
8) Maekawa Y, et al : Comprehensive Geriatric Assessment is a useful predictive tool for postoperative delirium after gastrointestinal surgery in old-old adults. Geriatr Gerontol Int 16 : 1036-1042, 2016.
PubMed
9) Mokutani Y, et al : Prediction of Postoperative Complications Following Elective Surgery in Elderly Patients with Colorectal Cancer Using the Comprehensive Geriatric Assessment. Dig Surg 33 : 470-477, 2016.
PubMed
10) Hamaker ME, et al : Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer : a systematic review. Lancet Oncol 13 : e437-444, 2012.
 
11) Copeland GP, et al : POSSUM : a scoring system for surgical audit. Br J Surg 78 : 355-360, 1991.
PubMed
12) Haga Y, et al : Evaluation of an Estimation of Physiologic Ability and Surgical Stress (E-PASS) scoring system to predict postoperative risk : a multicenter prospective study. Surg Today 31 : 569-574, 2001.
 
13) 小濱和貴, ほか : 高齢者の消化器癌手術における術前リスク評価と治療方針選択の実態 : 京大外科関連施設癌研究会アンケート調査から. 日本外科学会雑誌 118 : 325-331, 2017.
 
14) National clinical database. [http://www.ncd.or.jp/] (2017年7月閲覧)
 
15) Sanders RD, et al : Risk factors for postoperative delirium. Lancet Psychiatry 1 : 404-406, 2014.
PubMed
16) Chang YL, et al : Prevalence and risk factors for postoperative delirium in a cardiovascular intensive care unit. Am J Crit Care 17 : 567-575, 2008.
 
17) Drews T, et al : Postoperative delirium is an independent risk factor for posttraumatic stress disorder in the elderly patient : a prospective observational study. Eur J Anaesthesiol 32 : 147-151, 2015.
 
18) Schweickert WD, et al : Early physical and occupational therapy in mechanically ventilated, critically ill patients : a randomised controlled trial. Lancet 373 : 1874-1882, 2009.
PubMed
19) Ely EW, et al : Evaluation of delirium in critically ill patients : validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med 29 : 1370-1379, 2001.
PubMed
20) Siddiqi N, et al : Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev 3 : CD005563, 2016.
PubMed
21) Neufeld KJ, et al : Antipsychotic Medication for Prevention and Treatment of Delirium in Hospitalized Adults : A Systematic Review and Meta-Analysis. J Am Geriatr Soc 64 : 705-714, 2016.
PubMed
22) Gilmore ML, Wolfe DJ : Antipsychotic prophylaxis in surgical patients modestly decreases delirium incidence-but not duration-in high-incidence samples : a meta-analysis. Gen Hosp Psychiatry 35 : 370-375, 2013.
 
23) 添田暢俊, ほか : 消化器外科術後せん妄に対する抑肝散座薬の効果. 日本腹部救急医学会雑誌 35 : 11-18, 2015.
 
24) 高瀬信弥, 横山斉 : 術後せん妄 抑肝散 心臓大血管手術後せん妄の予防効果 (漢方を上手に使う-エビデンスに基づいた外科診療 周術期管理・合併症と漢方). 臨床外科 68 : 1314-1318, 2013.
 
25) Su X, et al : Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery : a randomised, double-blind, placebo-controlled trial. Lancet 388 : 1893-1902, 2016.
PubMed
26) Pasin L, et al : Dexmedetomidine reduces the risk of delirium, agitation and confusion in critically ill patients : a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 28 : 1459-1466, 2014.
PubMed
27) Macht M, et al : ICU-acquired swallowing disorders. Crit Care Med 41 : 2396-2405, 2013.
PubMed

IX 認知症患者とその家族を支える社会支援体制

P.402 掲載の参考文献
1) World Population Prospects. The 2017 Revision. [https://esa.un.org/unpd/wpp/Download/Standard/Population/] (2017年9月閲覧)
 
2) 厚生労働省 : 平成26年 (2014年) 患者調査の概況 [http://www.mhlw.go.jp/toukei/saikin/hw/kanja/14/index.html] (2017年9月閲覧)
 
3) 朝田隆 : 都市部における認知症有病率と認知症の生活機能障害への対応. 平成24年度厚生労働科学研究費補助金認知症対策総合研究事業 (研究代表者朝田隆) 報告書. [https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201218011A] (2017年9月閲覧)
 
4) 二宮利治 : 日本における認知症高齢者人口の将来推計に関する研究. 平成26年度厚生労働科学研究費補助金特別研究事業 (研究代表者二宮利治) 報告書 [https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201405037A] (2017年9月閲覧)
 
5) 公衆衛生審議会 : 老人精神保健対策に関する意見. 1982年11月. [http://www.ipss.go.jp/publication/j/shiryou/no.13/data/shiryou/syakaifukushi/202.pdf] (2017年9月閲覧)
 
6) 高齢者介護研究会 : 2015年の高齢者介護 : 高齢者の尊厳を支えるケアの確立に向けて. 2003年6月. [http://www.ipss.go.jp/publication/j/shiryou/no.13/data/shiryou/syakaifukushi/965.pdf] (2017年9月閲覧)
 
7) 厚生労働省 : 認知症の医療と生活の質を高める緊急プロジェクト. 2008年7月. [http://www.mhlw.go.jp/houdou/2008/07/dl/h0710-1a.pdf] (2017年9月閲覧)
 
8) 厚生労働省社会保障審議会介護保険部会 : 介護保険制度の見直しに関する意見. 2010年11月. [http://www.mhlw.go.jp/stf/shingi/2r9852000001rgu8-att/2r9852000001rl3r.pdf] (2017年9月閲覧)
 
9) 厚生労働省 : 今後の認知症施策の方向性について. 2012年6月. [http://wwwmhlw.go.jp/stf/shingi/2r9852000002fv2e-att/2r9852000002fv5j.pdf] (2017年9月閲覧)
 
10) 厚生労働省 : 認知症施策推進5か年計画 (オレンジプラン). 2012年8月. [http://www.mhlw.go.jp/stf/houdou/2r9852000002j8dh-att/2r9852000002j8ey.pdf] (2017年9月閲覧)
 
11) 厚生労働省 : 認知症施策推進総合戦略～認知症高齢者等にやさしい地域づくりに向けて～ (新オレンジプラン). 2015年1月. [http://www.mhlw.go.jp/stf/houdou/0000072246.html] (2017年9月閲覧)
 
12) 厚生労働省 : 認知症施策推進総合戦略 (新オレンジプラン) の数値目標の更新等について. 2017年7月. [http://wwwmhlw.go.jp/file/05-Shingikai-12301000-Roukenkyoku-Soumuka/0000146425_2.pdf] (2017年9月閲覧)
 
13) 粟田主一 : 認知症の人の視点を重視した生活実態調査と施策への反映方法に関する研究. 老年精神医学雑誌 28 (増刊号 1) : 34-40, 2017.
 
14) 粟田主一 : Dementia Friendly Communityの理念と世界の動き. 老年精神医学雑誌 28 : 458-465, 2017.
Medical*Online
P.408 掲載の参考文献
1) 櫻井博文, ほか : 大学病院側からみた病診連携の現状と課題. Progress in Medicine 34 : 841-843, 2014.
Medical*Online
2) 櫻井博文 : 認知症疾患医療センターへの取り組み. 東京医科大学雑誌 75 : 66-73, 2017.
Medical*Online
3) Hanyu H, et al : The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord 22 : 379-384, 2006.
 
4) Shimizu S, et al : Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. Eur J Nucl Med Mol Imaging 43 : 184-192, 2016.
PubMed
5) Iwamoto T, et al : Newly developed comprehensive geriatric assessment initiative "Dr. SUPERMAN" as a convenient screening test. Geriatr Gerontol Int 13 : 811-812, 2013.
PubMed
6) Namioka N, et al : Comprehensive geriatric assessment in elderly patients with dementia. Geriatr Gerontol Int 15 : 27-33, 2015.
PubMed
7) Namioka N, et al : Geriatric problems correlated with cognitive decline using a screening test named "Dr. SUPERMAN"for comprehensive geriatric assessment in elderly inpatients. Geriatr Gerontol Int 17 : 1252-1256, 2017.
PubMed
8) Sakurai H, et al : Factors associated with the burden of caregivers of patients with dementia. Geriatr Gerontol Int 15 : 384-385, 2015.
PubMed
9) Terayama H, et al : Caregiver's education decreases depression symptoms and burden in caregivers of patients with dementia. Psychogeriatrics (submitted).
 
10) Sakurai H, et al : Effects of day service use on the progression of Alzheimer's disease. J Am Geriatr Soc 62 : 1383-1384, 2014.
PubMed
11) Sakurai H, et al : Prevalence of coexisting diseases in patients with Alzheimer's disease. Geriatr Gerontol Int 10 : 216-217, 2010.
PubMed
12) Sakurai H, et al : Vascular risk factors and progression in Alzheimer's disease. Geriatr Gerontol Int 11 : 211-214, 2011.
PubMed
13) 日本老年医学会 (編) : 健康長寿診療ハンドブック-実地医家のための老年医学のエッセンス, メジカルビュー社, 2011.
 
14) Okita M, et al : Missing Incidents in Individuals with Dementia Attending a Memory Clinic. J Am Geriatr Soc 64 : 1365-1366, 2016.
PubMed
P.415 掲載の参考文献
1) 池田学, ほか : 認知症疾患医療センターの役割と今後の方向性 熊本モデルを中心に. 老年精神医学雑誌 21 : 1189-1192, 2010.
Medical*Online
2) 粟田主一 : 認知症疾患医療センター運営事業実績調査. 平成28年度老人保健健康増進等事業「認知症疾患医療センターの機能評価に関する調査研究事業」報告書. 東京都健康長寿医療センター, p11-70, 2017.
 
3) 粟田主一 : 認知症疾患医療センター機能評価-外部評価パイロット調査. 平成28年度老人保健健康増進等事業「認知症疾患医療センターの機能評価に関する調査研究事業」報告書. 東京都健康長寿医療センター, p71-116, 2017,
 
4) 大辻誠司, ほか : 全国認知症疾患医療センターの現状と課題について～アンケート調査報告～. 老年精神医学雑誌 27 : 554-560, 2016.
Medical*Online
5) 粟田主一 : 都道府県・指定都市における認知症疾患医療センターの質の管理に関する取り組みの実態について. 平成27年度老人保健健康増進等事業「認知症疾患医療センターの実態に関する調査研究事業」報告書. 東京都健康長寿医療センター, p201-232, 2016.
 
P.421 掲載の参考文献
1) 厚生労働省ホームページ : (参考) 認知症初期集中支援チームについて. [http://www.mhlw.go.jp/file/06-Seisakujouhou-12600000-Seisakutoukatsukan/OOOOO35310.pdf]
 
2) 国立長寿医療研修センター : 平成28年度認知症初期集中支援チーム員研修テキスト. [http://www.ncgg.go.jp/kenshu/kenshu/27-2.html]
 
3) 国立長寿医療研修センターホームページ. [http://www.ncgg.go.jp/kenshu/news/20161117.html]
 
4) 町田綾子 : Dementia Behavior Disturbance Scale (DBD) 短縮版の作成および信頼性, 妥当性の検討-ケア感受性の高い行動障害スケールの作成を目指して-. 日本老年医学会雑誌 49 : 463-467, 2012.
 
5) 荒井由美子, ほか : Zarit介護負担尺度日本語版の短縮版 (J-ZBI_8) の作成 : その信頼性と妥当性に関する検討. 日本老年医学会雑誌 40 : 497-503, 2003.
 
6) 粟田主一, ほか : 地域在住高齢者を対象とする地域包括ケアシステムにおける認知症アセスメントシート (DASC-21) の内的信頼性・妥当性に関する研究. 老年精神医学雑誌 26 : 675-686, 2015.
Medical*Online
7) 上村さと美, 秋山純和 : Zarit介護負担尺度日本語版 (J-ZBI) を用いた家族介護者の介護負担感評価. 理学療法科学 22 : 61-65, 2007.
Medical*Online
P.427 掲載の参考文献
1) トム・キットウッド : 認知症のパーソンセンタードケア, 筒井書房, 2005.
 
2) 武地一 : アルツハイマー型認知症の認知機能障害, 生活障害, BPSDの構造. 精神医学 58 : 905-913, 2016.
 
3) 今後の認知症施策の方向性について. [http://www.mhlw.go.jp/stf/shingi/2r9852000002fv2e-att/2r9852000002fv5j.pdf] (2017年9月閲覧)
 
4) World Health Organization and Alzheimer's Disease International : Dementia : a Public Health Priority, 2012. [http://whqlibdoc.who.int/publications/2012/9789241564458_eng.pdf] (2017年9月閲覧)
 
5) 認知症施策推進総合戦略 (新オレンジプラン). [http://www.mhlw.go.jp/stf/houdou/0000072246.html.] (2017年9月閲覧)
 
6) 武地一 : 認知症診療における認知症カフェの役割. 内科 120 : 229-232, 2017.
 
7) 武地一 : 認知症カフェハンドブック, クリエイツかもがわ, 2015.
 
8) 矢吹知之 : 認知症カフェ読本 : 知りたいことがわかるQ&Aと実践事例, 中央法規出版, 2016.
 
9) 石橋典子 : 「仕舞」としての呆け-認知症の人から学んだことば, 中央法規出版, 2007.
 
10) 藤本直規 : 認知症の医療とケア-「もの忘れクリニック」「もの忘れカフェ」の挑戦, クリエイツかもがわ, 2008.
 
11) 認知症施策の推進 (参考資料). [http://www.mhlw.go.jp/file/05-Shingikai-12601000-Seisakutoukatsukan-Sanjikanshitsu_Shakaihoshoutantou/0000136026.pdf] (2017年9月閲覧)
 
12) 「認知症カフェの実態に関する調査研究事業」報告書. 2017.
 
13) 武地一 : 認知症地域連携における認知症カフェの役割. 日本老年医学会雑誌 52 : 147-152, 2015.
 
14) 武地一 : ようこそ, 認知症カフェへ, ミネルヴァ書房, 2017.
 
P.433 掲載の参考文献
1) 高見国生 : ああ認知症家族-つながれば, 希望が見えてくる-, 岩波書店, 2011.
 
2) Arthur Kleinman (大橋英寿, ほか訳) : 臨床人類学-文化のなかの病者と治療者, 弘文堂, 1992.
 
3) 「家族の会」20周年記念誌, 25周年記念誌, 30周年記念誌, 35周年記念誌.
 
4) Christine Bryden (馬籠久美子訳) : 認知症とともに生きる私-「絶望」を「希望」に変えた20年, 大月書店, 2017.
 
5) NPO法人認知症当事者の会 (編) : 扉を開く人クリスティーン・ブライデン, クリエイツかもがわ, 2012.
 
6) 生井久美子 : ルポ希望の人々, 朝日新聞出版, 2017.
 
7) 越智須美子, 越智俊二 : あなたが認知症になったから. あなたが認知症にならなかったら., 中央法規出版, 2009.
 
8) 太田正博, ほか : 「私, バリバリの認知症です」, クリエイツかもがわ, 2006.
 
9) 佐藤雅彦 : 認知症になった私が伝えたいこと. 大月書店, 2014.
 
10) 中村成信 : ぼくが前を向いて歩く理由 (わけ) -事件, ピック病を超えて, いまを生きる, 中央法規出版, 2011.
 
11) 藤田和子 : 認知症になってもだいじょうぶ1そんな社会を創っていこうよ, 徳間書店, 2017.
 
12) 丹野智文 : 丹野智文笑顔で生きる-認知症とともに-, 文藝春秋, 2017.
 
13) 本人ミーティング開催ガイドブック [http://wwwmhlw.go.jp/stf/seisakunitsuite/bunya/0000167700.html] (2017年8月閲覧)
 
14) 山崎英樹 : Dementia Friendly Communityとはなにか～宮城県仙台市の経験. 老年精神医学雑誌 28 : 503-510, 2017.
 
15) 林真由美 : 認知症とともに生きる人々のための権利と権利ベースのアプローチ. 精神医学 59 : 739-748, 2017.
 
P.441 掲載の参考文献
1) 小竹雅子 : もっと変わる! 介護保険 (岩波ブックレット No. 907), p12-14, 2014.
 
2) 鳥海和輝, 三輪恭子 : 5. 介護保険の仕組みと考え方. 診療報酬・介護報酬のしくみと考え方, 第3版 (福井トシ子, 齋藤訓子編), p27-32, 日本看護協会出版会, 2016.
 
3) 上野昌江 : 市町村の高齢者福祉領域および地域包括支援センターの保健師活動. 公衆衛生看護学 (津村智恵子, 上野昌江編), p128-137, 中央法規出版, 2012.
 
4) 小竹雅子 : もっと変わる! 介護保険 (岩波ブックレット No. 907), p2-6, p21-44, 2014.
 
P.446 掲載の参考文献
1) 二木立 : 地域包括ケアと福祉改革, 勁草書房, 2017.
 
2) 伊藤周平, 日下部雅喜 : 改定介護保険法と自治体の役割-新総合事業と地域包括ケアシステムへの課題 [新版], 自治体研究所, 2016.
 
3) 地域包括ケア研究会 : 地域包括ケア研究会報告書「地域包括ケアシステムの構築」(平成27年度地域づくりによる介護予防推進支援事業). [http://www.mhlw.go.jp/file/05-Shingikai-12301000-Roukenkyoku-Soumuka/0000086353.pdf[ (2017年11月閲覧)
 
4) 松田晋哉 : 平成27年度の介護保険制度改正と報酬改定が目指すもの. 介護保険情報 15 (9), 14-19, 2014.
 
5) 座談会 : 新しい「介護予防・日常生活支援総合事業」の実施に向けて (石田光広・早川仁・前田耕作・高橋謙司). 介護保険情報 15 (8), 6-19, 2014.
 
6) 全国社会福祉協議会 : 助け合い活動ができる地域づくりを-生活支援サービス推進セミナー開催. 介護保険情報 15 (8), 20-23, 2014.
 
7) 内海久美子 : 地域包括ケアってなあに? 地域で見守る認知症. 医学と看護社, 2016.
 
8) 高橋誠一, ほか (編) : 生活支援コーディネーターと協議体, 全国コミュニティライフサポートセンター (CLC), 2015.
 
9) 特定非営利活動法人全国コミュニティライフサポートセンター : 生活支援体制整備事業をすすめるための市町村ガイドブック (平成28年度厚生労働省老人保健健康増進等事業), 2017.
 
10) 地域における医療及び介護の総合的な確保を推進するための関係法律の整備等に関する法律案要綱. 総確法. [http://www.mhlw.go.jp/topics/bukyoku/soumu/houritu/dl/186-07.pdf] (2017年11月閲覧)
 

アルツハイマー博士と最近の国際学会トピックス

P.448 掲載の参考文献
1) コンラート・マウラー, ウルリケ・マウラー著, 新井公人監訳 : 「アルツハイマー」-その生涯とアルツハイマー病発見の軌跡-, p235-236, 保健同人社, 2004.
 
2) Maurer K, et al : Auguste D and Alzheimer's disease. Lancet 349 : 1546-1549, 1997.
 
3) Alzheimer A : Uber eigenartige Krankheitsfalle des spateren Alters. Zeitschrift fUr die Gesamte Neurologie und Psychiatrie 4 : 356-385, 1911.
 
P.450 掲載の参考文献
1) Sperling RA, et al : Toward defining the preclinical stages of Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 : 280-292, 2011.
PubMed
2) Jack CR, et al : A/T/N : An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87 : 539-547, 2016.
 
3) Bateman RJ, et al : Clinical and biomarker changes in dominantly inherited Alzheimer's Disease. N Engl J Med 367 : 795-804, 2012.
PubMed
P.452 掲載の参考文献
1) Sevigny J, et al : The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537 : 50-56, 2016.
 
2) Sperling RA, et al : Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials : recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7 : 367-385, 2011.
PubMed
3) Villemagne VL et al : Tau imaging : early progress and future directions. Lancet Neurol 14 : 114-124, 2015.
PubMed
4) Braak H, et al : Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112 : 389-404, 2006.
PubMed
5) Bateman RJ, et al ; Dominantly Inherited Alzheimer Network : Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 : 795-804, 2012.
PubMed
6) van Eimeren T, et al : Is tau imaging more than just "upside-down" 18F-FDG imaging? J Nucl Med 58 : 1357-1359, 2017.
PubMed
P.454 掲載の参考文献
1) http://www.usagainstalzheimers.org/networks/researchers
 
2) http://www.usagainstalzheimers.org/our-board
 
3) http://www.usagainstalzheimers.org/our-mission
 

書評

最近チェックした商品履歴

Loading...